<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of SB1773</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					SB1773 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>SB1773</pre></b></center><p> </p>Introduced 2/5/2025, by Sen. Julie A. Morrison<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>720 ILCS 570/102</code></td><td class="synopsis"><code>  </code><code>from Ch. 56 1/2, par. 1102</code></td></tr><tr><td class="synopsis"><code>720 ILCS 570/204</code></td><td class="synopsis"><code>  </code><code>from Ch. 56 1/2, par. 1204</code></td></tr><tr><td class="synopsis"><code>720 ILCS 570/206</code></td><td class="synopsis"><code>  </code><code>from Ch. 56 1/2, par. 1206</code></td></tr><tr><td class="synopsis"><code>720 ILCS 570/208</code></td><td class="synopsis"><code>  </code><code>from Ch. 56 1/2, par. 1208</code></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Amends the Illinois Controlled Substances Act. Makes structural and </code><code>other changes to the list of controlled substances. Adds xylazine as a </code><code>Class III controlled substance. Defines "isomer". Effective January 1, </code><code>2026.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning criminal law.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>The Illinois Controlled Substances Act is </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>amended by changing Sections 102, 204, 206, and 208 as </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>follows:</code><br> </td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(720 ILCS 570/102)</code><code>  </code><code>(from Ch. 56 1/2, par. 1102)</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(Text of Section before amendment by P.A. 103-881</code><code>)</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 102. </code><code>Definitions. </code><code> As used in this Act, unless the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>context otherwise requires: </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) "Addict" means any person who habitually uses any </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>drug, chemical, substance or dangerous drug other than alcohol </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>so as to endanger the public morals, health, safety or welfare </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>or who is so far addicted to the use of a dangerous drug or </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>controlled substance other than alcohol as to have lost the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>power of self control with reference to his or her addiction. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) "Administer" means the direct application of a </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>controlled substance, whether by injection, inhalation, </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>ingestion, or any other means, to the body of a patient, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>research subject, or animal (as defined by the Humane </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>Euthanasia in Animal Shelters Act) by: </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) a practitioner (or, in his or her presence, by his </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>or her authorized agent), </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) the patient or research subject pursuant to an </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>order, or </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) a euthanasia technician as defined by the Humane </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>Euthanasia in Animal Shelters Act. </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) "Agent" means an authorized person who acts on behalf </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>of or at the direction of a manufacturer, distributor, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>dispenser, prescriber, or practitioner. It does not include a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>common or contract carrier, public warehouseman or employee of </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the carrier or warehouseman. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c-1) "Anabolic Steroids" means any drug or hormonal </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>substance, chemically and pharmacologically related to </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>testosterone (other than estrogens, progestins, </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>corticosteroids, and dehydroepiandrosterone), and includes: </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) 3[beta],17-dihydroxy-5a-androstane, </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(iii) 5[alpha]-androstan-3,17-dione, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(iv) 1-androstenediol (3[beta], </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-dihydroxy-5[alpha]-androst-1-ene), </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(v) 1-androstenediol (3[alpha], </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-dihydroxy-5[alpha]-androst-1-ene), </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(vi) 4-androstenediol  </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3[beta],17[beta]-dihydroxy-androst-4-ene), </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(vii) 5-androstenediol  </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3[beta],17[beta]-dihydroxy-androst-5-ene), </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(viii) 1-androstenedione  </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>([5alpha]-androst-1-en-3,17-dione), </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ix) 4-androstenedione  </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(androst-4-en-3,17-dione), </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(x) 5-androstenedione  </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(androst-5-en-3,17-dione), </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xii) boldenone (17[beta]-hydroxyandrost- </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>1,4,-diene-3-one), </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xiii) boldione (androsta-1,4- </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>diene-3,17-dione), </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xiv) calusterone (7[beta],17[alpha]-dimethyl-17 </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>[beta]-hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xv) clostebol (4-chloro-17[beta]- </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xvi) dehydrochloromethyltestosterone (4-chloro- </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-hydroxy-17[alpha]-methyl- </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androst-1,4-dien-3-one), </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xvii) desoxymethyltestosterone </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>(17[alpha]-methyl-5[alpha] </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>-androst-2-en-17[beta]-ol)(a.k.a., madol), </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xviii) [delta]1-dihydrotestosterone (a.k.a.  </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>'1-testosterone') (17[beta]-hydroxy- </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>5[alpha]-androst-1-en-3-one), </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xix) 4-dihydrotestosterone (17[beta]-hydroxy- </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androstan-3-one), </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>5[alpha]-androstan-3-one), </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-ene), </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>1[beta],17[beta]-dihydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-dihydroxyandrost-1,4-dien-3-one), </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxiv) furazabol (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrostano[2,3-c]-furazan), </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androst-4-en-3-one), </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxy-estr-4-en-3-one), </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxviii) mestanolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxy-5-androstan-3-one), </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxix) mesterolone (1amethyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>[5a]-androstan-3-one), </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxx) methandienone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-1,4-dien-3-one), </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyandrost-5-ene), </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxii) methenolone (1-methyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>5[alpha]-androst-1-en-3-one), </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxy-5a-androstane, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 5 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>-5a-androstane, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxv) 17[alpha]-methyl-3[beta],17[beta]- </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyandrost-4-ene), </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestra-4,9(10)-dien-3-one), </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestra-4,9-11-trien-3-one), </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>1-testosterone'), </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-4-ene), </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-4-ene), </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-5-ene), </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 6 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-5-ene), </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlvii) 19-nor-4,9(10)-androstadienedione  </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(estra-4,9(10)-diene-3,17-dione), </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlviii) 19-nor-4-androstenedione (estr-4- </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>en-3,17-dione), </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlix) 19-nor-5-androstenedione (estr-5- </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>en-3,17-dione), </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(l) norbolethone (13[beta], 17a-diethyl-17[beta]- </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxygon-4-en-3-one), </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(li) norclostebol (4-chloro-17[beta]- </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lii) norethandrolone (17[alpha]-ethyl-17[beta]- </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(liii) normethandrolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>2-oxa-5[alpha]-androstan-3-one), </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lv) oxymesterone (17[alpha]-methyl-4,17[beta]- </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-hydroxy-(5[alpha]-androstan-3-one), </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5[alpha]-androst-2-eno[3,2-c]-pyrazole), </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lviii) stenbolone (17[beta]-hydroxy-2-methyl- </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5[alpha]-androst-1-en-3-one), </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lix) testolactone (13-hydroxy-3-oxo-13,17- </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 7 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>secoandrosta-1,4-dien-17-oic </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>acid lactone), </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lx) testosterone (17[beta]-hydroxyandrost- </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>4-en-3-one), </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lxi) tetrahydrogestrinone (13[beta], 17[alpha]- </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>diethyl-17[beta]-hydroxygon- </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>4,9,11-trien-3-one), </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lxii) trenbolone (17[beta]-hydroxyestr-4,9, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>11-trien-3-one). </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Any person who is otherwise lawfully in possession of an </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>anabolic steroid, or who otherwise lawfully manufactures, </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>distributes, dispenses, delivers, or possesses with intent to </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>deliver an anabolic steroid, which anabolic steroid is </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>expressly intended for and lawfully allowed to be administered </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>through implants to livestock or other nonhuman species, and </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>which is approved by the Secretary of Health and Human </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Services for such administration, and which the person intends </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>to administer or have administered through such implants, </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>shall not be considered to be in unauthorized possession or to </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>unlawfully manufacture, distribute, dispense, deliver, or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>possess with intent to deliver such anabolic steroid for </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>purposes of this Act. </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) "Administration" means the Drug Enforcement </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>Administration, United States Department of Justice, or its </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>successor agency. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d-5) "Clinical Director, Prescription Monitoring Program" </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 8 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>means a Department of Human Services administrative employee </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>licensed to either prescribe or dispense controlled substances </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>who shall run the clinical aspects of the Department of Human </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>Services Prescription Monitoring Program and its Prescription </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Information Library.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d-10) "Compounding" means the preparation and mixing of </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>components, excluding flavorings, (1) as the result of a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>prescriber's prescription drug order or initiative based on </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the prescriber-patient-pharmacist relationship in the course </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>of professional practice or (2) for the purpose of, or </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>incident to, research, teaching, or chemical analysis and not </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>for sale or dispensing. "Compounding" includes the preparation </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>of drugs or devices in anticipation of receiving prescription </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>drug orders based on routine, regularly observed dispensing </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>patterns. Commercially available products may be compounded </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>for dispensing to individual patients only if both of the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>following conditions are met: (i) the commercial product is </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>not reasonably available from normal distribution channels in </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>a timely manner to meet the patient's needs and (ii) the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>prescribing practitioner has requested that the drug be </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>compounded. </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) "Control" means to add a drug or other substance, or </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>immediate precursor, to a Schedule whether by transfer from </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>another Schedule or otherwise. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) "Controlled Substance" means (i) a drug, substance, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>immediate precursor, or synthetic drug in the Schedules of </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 9 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Article II of this Act or (ii) a drug or other substance, or </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>immediate precursor, designated as a controlled substance by </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>the Department through administrative rule. The term does not </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>include distilled spirits, wine, malt beverages, or tobacco, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>as those terms are defined or used in the Liquor Control Act of </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>1934 and the Tobacco Products Tax Act of 1995. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f-5) "Controlled substance analog" means a substance:</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the chemical structure of which is substantially </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>similar to the chemical structure of a controlled </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>substance in Schedule I or II;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) which has a stimulant, depressant, or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>hallucinogenic effect on the central nervous system that </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>is substantially similar to or greater than the stimulant, </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>depressant, or hallucinogenic effect on the central </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>nervous system of a controlled substance in Schedule I or </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>II; or</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) with respect to a particular person, which such </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>person represents or intends to have a stimulant, </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>depressant, or hallucinogenic effect on the central </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>nervous system that is substantially similar to or greater </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>than the stimulant, depressant, or hallucinogenic effect </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>on the central nervous system of a controlled substance in </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>Schedule I or II. </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) "Counterfeit substance" means a controlled substance, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>which, or the container or labeling of which, without </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>authorization bears the trademark, trade name, or other </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 10 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>identifying mark, imprint, number or device, or any likeness </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>thereof, of a manufacturer, distributor, or dispenser other </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>than the person who in fact manufactured, distributed, or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>dispensed the substance. </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) "Deliver" or "delivery" means the actual, constructive </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or attempted transfer of possession of a controlled substance, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>with or without consideration, whether or not there is an </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>agency relationship. "Deliver" or "delivery" does not include </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the donation of drugs to the extent permitted under the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>Illinois Drug Reuse Opportunity Program Act. </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) "Department" means the Illinois Department of Human </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Services (as successor to the Department of Alcoholism and </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Substance Abuse) or its successor agency. </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(j) (Blank). </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(k) "Department of Corrections" means the Department of </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Corrections of the State of Illinois or its successor agency. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(l) "Department of Financial and Professional Regulation" </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>means the Department of Financial and Professional Regulation </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>of the State of Illinois or its successor agency. </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(m) "Depressant" means any drug that (i) causes an overall </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>depression of central nervous system functions, (ii) causes </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>impaired consciousness and awareness, and (iii) can be </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>habit-forming or lead to a substance abuse problem, including, </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>but not limited to, alcohol, cannabis and its active </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>principles and their analogs, benzodiazepines and their </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>analogs, barbiturates and their analogs, opioids (natural and </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 11 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>synthetic) and their analogs, and chloral hydrate and similar </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>sedative hypnotics. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(n) (Blank). </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(o) "Director" means the Director of the Illinois State </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Police or his or her designated agents. </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(p) "Dispense" means to deliver a controlled substance to </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>an ultimate user or research subject by or pursuant to the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>lawful order of a prescriber, including the prescribing, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>administering, packaging, labeling, or compounding necessary </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>to prepare the substance for that delivery. </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(q) "Dispenser" means a practitioner who dispenses. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(r) "Distribute" means to deliver, other than by </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>administering or dispensing, a controlled substance. </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(s) "Distributor" means a person who distributes. </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t) "Drug" means (1) substances recognized as drugs in the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>official United States Pharmacopoeia, Official Homeopathic </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Pharmacopoeia of the United States, or official National </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>Formulary, or any supplement to any of them; (2) substances </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>intended for use in diagnosis, cure, mitigation, treatment, or </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>prevention of disease in man or animals; (3) substances (other </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>than food) intended to affect the structure of any function of </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>the body of man or animals and (4) substances intended for use </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>as a component of any article specified in clause (1), (2), or </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>(3) of this subsection. It does not include devices or their </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>components, parts, or accessories. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-3) "Electronic health record" or "EHR" means an </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 12 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>electronic record of health-related information on an </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>individual that is created, gathered, managed, and consulted </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>by authorized health care clinicians and staff. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-3.5) "Electronic health record system" or "EHR system" </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>means any computer-based system or combination of federally </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>certified Health IT Modules (defined at 42 CFR 170.102 or its </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>successor) used as a repository for electronic health records </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>and accessed or updated by a prescriber or authorized </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>surrogate in the ordinary course of his or her medical </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>practice. For purposes of connecting to the Prescription </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Information Library maintained by the Bureau of Pharmacy and </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Clinical Support Systems or its successor, an EHR system may </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>connect to the Prescription Information Library directly or </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>through all or part of a computer program or system that is a </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>federally certified Health IT Module maintained by a third </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>party and used by the EHR system to secure access to the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>database.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-4) "Emergency medical services personnel" has the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>meaning ascribed to it in the Emergency Medical Services (EMS) </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Systems Act.</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-5) "Euthanasia agency" means an entity certified by the </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>Department of Financial and Professional Regulation for the </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>purpose of animal euthanasia that holds an animal control </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>facility license or animal shelter license under the Animal </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>Welfare Act. A euthanasia agency is authorized to purchase, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>store, possess, and utilize Schedule II nonnarcotic and </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 13 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Schedule III nonnarcotic drugs for the sole purpose of animal </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>euthanasia. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-10) "Euthanasia drugs" means Schedule II or Schedule </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>III substances (nonnarcotic controlled substances) that are </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>used by a euthanasia agency for the purpose of animal </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>euthanasia. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u) "Good faith" means the prescribing or dispensing of a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>controlled substance by a practitioner in the regular course </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>of professional treatment to or for any person who is under his </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>or her treatment for a pathology or condition other than that </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>individual's physical or psychological dependence upon or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>addiction to a controlled substance, except as provided </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>herein: and application of the term to a pharmacist shall mean </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>the dispensing of a controlled substance pursuant to the </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>prescriber's order which in the professional judgment of the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>pharmacist is lawful. The pharmacist shall be guided by </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>accepted professional standards, including, but not limited </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>to, the following, in making the judgment: </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) lack of consistency of prescriber-patient </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>relationship, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) frequency of prescriptions for same drug by one </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>prescriber for large numbers of patients, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) quantities beyond those normally prescribed, </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) unusual dosages (recognizing that there may be </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>clinical circumstances where more or less than the usual </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>dose may be used legitimately), </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 14 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) unusual geographic distances between patient, </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>pharmacist and prescriber, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) consistent prescribing of habit-forming drugs. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u-0.5) "Hallucinogen" means a drug that causes markedly </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>altered sensory perception leading to hallucinations of any </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>type. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u-1) "Home infusion services" means services provided by </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>a pharmacy in compounding solutions for direct administration </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>to a patient in a private residence, long-term care facility, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>or hospice setting by means of parenteral, intravenous, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>intramuscular, subcutaneous, or intraspinal infusion. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u-5) "Illinois State Police" means the Illinois State </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Police or its successor agency. </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(v) "Immediate precursor" means a substance: </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) which the Department has found to be and by rule </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>designated as being a principal compound used, or produced </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>primarily for use, in the manufacture of a controlled </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>substance; </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) which is an immediate chemical intermediary used </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>or likely to be used in the manufacture of such controlled </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>substance; and </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the control of which is necessary to prevent, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>curtail or limit the manufacture of such controlled </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>substance. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(w) "Instructional activities" means the acts of teaching, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>educating or instructing by practitioners using controlled </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 15 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>substances within educational facilities approved by the State </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>Board of Education or its successor agency. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(x) "Local authorities" means a duly organized State, </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>County or Municipal peace unit or police force. </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(y) "Look-alike substance" means a substance, other than a </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>controlled substance which (1) by overall dosage unit </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>appearance, including shape, color, size, markings or lack </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>thereof, taste, consistency, or any other identifying physical </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>characteristic of the substance, would lead a reasonable </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>person to believe that the substance is a controlled </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>substance, or (2) is expressly or impliedly represented to be </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>a controlled substance or is distributed under circumstances </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>which would lead a reasonable person to believe that the </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>substance is a controlled substance. For the purpose of </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>determining whether the representations made or the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>circumstances of the distribution would lead a reasonable </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>person to believe the substance to be a controlled substance </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>under this clause (2) of subsection (y), the court or other </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>authority may consider the following factors in addition to </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>any other factor that may be relevant: </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(a) statements made by the owner or person in control </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>of the substance concerning its nature, use or effect; </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(b) statements made to the buyer or recipient that the </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>substance may be resold for profit; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(c) whether the substance is packaged in a manner </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>normally used for the illegal distribution of controlled </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 16 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>substances; </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(d) whether the distribution or attempted distribution </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>included an exchange of or demand for money or other </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>property as consideration, and whether the amount of the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>consideration was substantially greater than the </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>reasonable retail market value of the substance. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Clause (1) of this subsection (y) shall not apply to a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>noncontrolled substance in its finished dosage form that was </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>initially introduced into commerce prior to the initial </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>introduction into commerce of a controlled substance in its </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>finished dosage form which it may substantially resemble. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Nothing in this subsection (y) prohibits the dispensing or </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>distributing of noncontrolled substances by persons authorized </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>to dispense and distribute controlled substances under this </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>Act, provided that such action would be deemed to be carried </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>out in good faith under subsection (u) if the substances </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>involved were controlled substances. </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Nothing in this subsection (y) or in this Act prohibits </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>the manufacture, preparation, propagation, compounding, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>processing, packaging, advertising or distribution of a drug </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>or drugs by any person registered pursuant to Section 510 of </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360). </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(y-1) "Mail-order pharmacy" means a pharmacy that is </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>located in a state of the United States that delivers, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>dispenses or distributes, through the United States Postal </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>Service or other common carrier, to Illinois residents, any </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 17 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>substance which requires a prescription. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z) "Manufacture" means the production, preparation, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>propagation, compounding, conversion or processing of a </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>controlled substance other than methamphetamine, either </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>directly or indirectly, by extraction from substances of </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>natural origin, or independently by means of chemical </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>synthesis, or by a combination of extraction and chemical </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>synthesis, and includes any packaging or repackaging of the </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>substance or labeling of its container, except that this term </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>does not include: </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) by an ultimate user, the preparation or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>compounding of a controlled substance for his or her own </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>use; </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) by a practitioner, or his or her authorized agent </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>under his or her supervision, the preparation, </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>compounding, packaging, or labeling of a controlled </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>substance: </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(a) as an incident to his or her administering or </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <code>dispensing of a controlled substance in the course of </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <code>his or her professional practice; or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(b) as an incident to lawful research, teaching or </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <code>chemical analysis and not for sale; or </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the packaging, repackaging, or labeling of drugs </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>only to the extent permitted under the Illinois Drug Reuse </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>Opportunity Program Act. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z-1) (Blank). </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 18 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z-5) "Medication shopping" means the conduct prohibited </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>under subsection (a) of Section 314.5 of this Act.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z-10) "Mid-level practitioner" means (i) a physician </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>assistant who has been delegated authority to prescribe </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>through a written delegation of authority by a physician </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>licensed to practice medicine in all of its branches, in </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 7.5 of the Physician Assistant </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>Practice Act of 1987, (ii) an advanced practice registered </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>nurse who has been delegated authority to prescribe through a </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>written delegation of authority by a physician licensed to </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>practice medicine in all of its branches or by a podiatric </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>physician, in accordance with Section 65-40 of the Nurse </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Practice Act, (iii) an advanced practice registered nurse </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>certified as a nurse practitioner, nurse midwife, or clinical </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>nurse specialist who has been granted authority to prescribe </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>by a hospital affiliate in accordance with Section 65-45 of </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>the Nurse Practice Act, (iv) an animal euthanasia agency, or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>(v) a prescribing psychologist. </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(aa) "Narcotic drug" means any of the following, whether </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>produced directly or indirectly by extraction from substances </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>of vegetable origin, or independently by means of chemical </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>synthesis, or by a combination of extraction and chemical </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>synthesis: </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) opium, opiates, derivatives of opium and opiates, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>including their isomers, esters, ethers, salts, and salts </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>of isomers, esters, and ethers, whenever the existence of </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 19 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>such isomers, esters, ethers, and salts is possible within </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>the specific chemical designation; however the term </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>"narcotic drug" does not include the isoquinoline </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>alkaloids of opium; </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) (blank); </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) opium poppy and poppy straw; </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) coca leaves, except coca leaves and extracts of </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>coca leaves from which substantially all of the cocaine </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>and ecgonine, and their isomers, derivatives and salts, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>have been removed; </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) cocaine, its salts, optical and geometric isomers, </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>and salts of isomers;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) ecgonine, its derivatives, their salts, isomers, </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>and salts of isomers;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) any compound, mixture, or preparation which </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>contains any quantity of any of the substances referred to </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>in subparagraphs (1) through (6). </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(bb) "Nurse" means a registered nurse licensed under the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act. </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(cc) (Blank). </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(dd) "Opiate" means any substance having an addiction </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>forming or addiction sustaining liability similar to morphine </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>or being capable of conversion into a drug having addiction </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>forming or addiction sustaining liability. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ee) "Opium poppy" means the plant of the species Papaver </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>somniferum L., except its seeds. </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 20 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ee-5) "Oral dosage" means a tablet, capsule, elixir, or </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>solution or other liquid form of medication intended for </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>administration by mouth, but the term does not include a form </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>of medication intended for buccal, sublingual, or transmucosal </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>administration. </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ff) "Parole and Pardon Board" means the Parole and Pardon </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Board of the State of Illinois or its successor agency. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(gg) "Person" means any individual, corporation, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>mail-order pharmacy, government or governmental subdivision or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>agency, business trust, estate, trust, partnership or </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>association, or any other entity. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(hh) "Pharmacist" means any person who holds a license or </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>certificate of registration as a registered pharmacist, a </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>local registered pharmacist or a registered assistant </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>pharmacist under the Pharmacy Practice Act. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii) "Pharmacy" means any store, ship or other place in </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>which pharmacy is authorized to be practiced under the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>Pharmacy Practice Act. </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii-5) "Pharmacy shopping" means the conduct prohibited </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>under subsection (b) of Section 314.5 of this Act.</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii-10) "Physician" (except when the context otherwise </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>requires) means a person licensed to practice medicine in all </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>of its branches. </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(jj) "Poppy straw" means all parts, except the seeds, of </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>the opium poppy, after mowing. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(kk) "Practitioner" means a physician licensed to practice </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 21 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>medicine in all its branches, dentist, optometrist, podiatric </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>physician, veterinarian, scientific investigator, pharmacist, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>physician assistant, advanced practice registered nurse, </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>licensed practical nurse, registered nurse, emergency medical </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>services personnel, hospital, laboratory, or pharmacy, or </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>other person licensed, registered, or otherwise lawfully </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>permitted by the United States or this State to distribute, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>dispense, conduct research with respect to, administer or use </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>in teaching or chemical analysis, a controlled substance in </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>the course of professional practice or research. </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ll) "Pre-printed prescription" means a written </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>prescription upon which the designated drug has been indicated </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>prior to the time of issuance; the term does not mean a written </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>prescription that is individually generated by machine or </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>computer in the prescriber's office. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(mm) "Prescriber" means a physician licensed to practice </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>medicine in all its branches, dentist, optometrist, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>prescribing psychologist licensed under Section 4.2 of the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>Clinical Psychologist Licensing Act with prescriptive </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>authority delegated under Section 4.3 of the Clinical </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>Psychologist Licensing Act, podiatric physician, or </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>veterinarian who issues a prescription, a physician assistant </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>who issues a prescription for a controlled substance in </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 303.05, a written delegation, and a </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>written collaborative agreement required under Section 7.5 of </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>the Physician Assistant Practice Act of 1987, an advanced </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 22 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>practice registered nurse with prescriptive authority </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>delegated under Section 65-40 of the Nurse Practice Act and in </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 303.05, a written delegation, and a </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>written collaborative agreement under Section 65-35 of the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act, an advanced practice registered nurse </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>certified as a nurse practitioner, nurse midwife, or clinical </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>nurse specialist who has been granted authority to prescribe </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>by a hospital affiliate in accordance with Section 65-45 of </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the Nurse Practice Act and in accordance with Section 303.05, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>or an advanced practice registered nurse certified as a nurse </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>practitioner, nurse midwife, or clinical nurse specialist who </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>has full practice authority pursuant to Section 65-43 of the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act. </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(nn) "Prescription" means a written, facsimile, or oral </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>order, or an electronic order that complies with applicable </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>federal requirements, of a physician licensed to practice </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>medicine in all its branches, dentist, podiatric physician or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>veterinarian for any controlled substance, of an optometrist </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>in accordance with Section 15.1 of the Illinois Optometric </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Practice Act of 1987, of a prescribing psychologist licensed </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>under Section 4.2 of the Clinical Psychologist Licensing Act </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>with prescriptive authority delegated under Section 4.3 of the </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>Clinical Psychologist Licensing Act, of a physician assistant </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>for a controlled substance in accordance with Section 303.05, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>a written delegation, and a written collaborative agreement </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>required under Section 7.5 of the Physician Assistant Practice </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 23 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Act of 1987, of an advanced practice registered nurse with </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>prescriptive authority delegated under Section 65-40 of the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act who issues a prescription for a controlled </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>substance in accordance with Section 303.05, a written </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>delegation, and a written collaborative agreement under </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>Section 65-35 of the Nurse Practice Act, of an advanced </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>practice registered nurse certified as a nurse practitioner, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>nurse midwife, or clinical nurse specialist who has been </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>granted authority to prescribe by a hospital affiliate in </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 65-45 of the Nurse Practice Act and in </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 303.05 when required by law, or of an </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>advanced practice registered nurse certified as a nurse </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>practitioner, nurse midwife, or clinical nurse specialist who </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>has full practice authority pursuant to Section 65-43 of the </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(nn-5) "Prescription Information Library" (PIL) means an </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>electronic library that contains reported controlled substance </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>data.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(nn-10) "Prescription Monitoring Program" (PMP) means the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>entity that collects, tracks, and stores reported data on </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>controlled substances and select drugs pursuant to Section </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>316. </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(oo) "Production" or "produce" means manufacture, </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>planting, cultivating, growing, or harvesting of a controlled </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>substance other than methamphetamine. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(pp) "Registrant" means every person who is required to </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 24 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>register under Section 302 of this Act. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(qq) "Registry number" means the number assigned to each </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>person authorized to handle controlled substances under the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>laws of the United States and of this State. </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(qq-5) "Secretary" means, as the context requires, either </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>the Secretary of the Department or the Secretary of the </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Department of Financial and Professional Regulation, and the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>Secretary's designated agents. </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(rr) "State" includes the State of Illinois and any state, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>district, commonwealth, territory, insular possession thereof, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>and any area subject to the legal authority of the United </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>States of America. </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(rr-5) "Stimulant" means any drug that (i) causes an </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>overall excitation of central nervous system functions, (ii) </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>causes impaired consciousness and awareness, and (iii) can be </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>habit-forming or lead to a substance abuse problem, including, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>but not limited to, amphetamines and their analogs, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>methylphenidate and its analogs, cocaine, and phencyclidine </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>and its analogs. </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(rr-10) "Synthetic drug" includes, but is not limited to, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>any synthetic cannabinoids or piperazines or any synthetic </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>cathinones as provided for in Schedule I. </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ss) "Ultimate user" means a person who lawfully possesses </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>a controlled substance for his or her own use or for the use of </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>a member of his or her household or for administering to an </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>animal owned by him or her or by a member of his or her </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 25 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>household. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22; </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)</code><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(Text of Section after amendment by P.A. 103-881</code><code>)</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 102. </code><code>Definitions. </code><code> As used in this Act, unless the </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>context otherwise requires: </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) "Person with a substance use disorder" means any </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>person who has a substance use disorder diagnosis defined as a </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>spectrum of persistent and recurring problematic behavior that </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>encompasses 10 separate classes of drugs: alcohol; caffeine; </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>cannabis; hallucinogens; inhalants; opioids; sedatives, </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>hypnotics and anxiolytics; stimulants; and tobacco; and other </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>unknown substances leading to clinically significant </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>impairment or distress. </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) "Administer" means the direct application of a </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>controlled substance, whether by injection, inhalation, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>ingestion, or any other means, to the body of a patient, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>research subject, or animal (as defined by the Humane </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>Euthanasia in Animal Shelters Act) by: </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) a practitioner (or, in his or her presence, by his </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>or her authorized agent), </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) the patient or research subject pursuant to an </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>order, or </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) a euthanasia technician as defined by the Humane </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>Euthanasia in Animal Shelters Act. </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 26 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) "Agent" means an authorized person who acts on behalf </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>of or at the direction of a manufacturer, distributor, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>dispenser, prescriber, or practitioner. It does not include a </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>common or contract carrier, public warehouseman or employee of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>the carrier or warehouseman. </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c-1) "Anabolic Steroids" means any drug or hormonal </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>substance, chemically and pharmacologically related to </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>testosterone (other than estrogens, progestins, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>corticosteroids, and dehydroepiandrosterone), and includes: </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) 3[beta],17-dihydroxy-5a-androstane, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(iii) 5[alpha]-androstan-3,17-dione, </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(iv) 1-androstenediol (3[beta], </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-dihydroxy-5[alpha]-androst-1-ene), </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(v) 1-androstenediol (3[alpha], </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-dihydroxy-5[alpha]-androst-1-ene), </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(vi) 4-androstenediol  </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3[beta],17[beta]-dihydroxy-androst-4-ene), </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(vii) 5-androstenediol  </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3[beta],17[beta]-dihydroxy-androst-5-ene), </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(viii) 1-androstenedione  </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>([5alpha]-androst-1-en-3,17-dione), </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ix) 4-androstenedione  </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(androst-4-en-3,17-dione), </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(x) 5-androstenedione  </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(androst-5-en-3,17-dione), </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 27 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xii) boldenone (17[beta]-hydroxyandrost- </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>1,4,-diene-3-one), </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xiii) boldione (androsta-1,4- </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>diene-3,17-dione), </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xiv) calusterone (7[beta],17[alpha]-dimethyl-17 </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>[beta]-hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xv) clostebol (4-chloro-17[beta]- </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xvi) dehydrochloromethyltestosterone (4-chloro- </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-hydroxy-17[alpha]-methyl- </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androst-1,4-dien-3-one), </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xvii) desoxymethyltestosterone </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>(17[alpha]-methyl-5[alpha] </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>-androst-2-en-17[beta]-ol)(a.k.a., madol), </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xviii) [delta]1-dihydrotestosterone (a.k.a.  </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>'1-testosterone') (17[beta]-hydroxy- </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>5[alpha]-androst-1-en-3-one), </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xix) 4-dihydrotestosterone (17[beta]-hydroxy- </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androstan-3-one), </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>5[alpha]-androstan-3-one), </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-ene), </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 28 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>1[beta],17[beta]-dihydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-dihydroxyandrost-1,4-dien-3-one), </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxiv) furazabol (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrostano[2,3-c]-furazan), </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androst-4-en-3-one), </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxy-estr-4-en-3-one), </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxviii) mestanolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxy-5-androstan-3-one), </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxix) mesterolone (1amethyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>[5a]-androstan-3-one), </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxx) methandienone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-1,4-dien-3-one), </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyandrost-5-ene), </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxii) methenolone (1-methyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>5[alpha]-androst-1-en-3-one), </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxy-5a-androstane, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>-5a-androstane, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxv) 17[alpha]-methyl-3[beta],17[beta]- </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyandrost-4-ene), </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 29 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestra-4,9(10)-dien-3-one), </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestra-4,9-11-trien-3-one), </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>1-testosterone'), </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-4-ene), </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-4-ene), </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-5-ene), </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyestr-5-ene), </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlvii) 19-nor-4,9(10)-androstadienedione  </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(estra-4,9(10)-diene-3,17-dione), </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlviii) 19-nor-4-androstenedione (estr-4- </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 30 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>en-3,17-dione), </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(xlix) 19-nor-5-androstenedione (estr-5- </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>en-3,17-dione), </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(l) norbolethone (13[beta], 17a-diethyl-17[beta]- </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxygon-4-en-3-one), </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(li) norclostebol (4-chloro-17[beta]- </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lii) norethandrolone (17[alpha]-ethyl-17[beta]- </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(liii) normethandrolone (17[alpha]-methyl-17[beta]- </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>hydroxyestr-4-en-3-one), </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>2-oxa-5[alpha]-androstan-3-one), </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lv) oxymesterone (17[alpha]-methyl-4,17[beta]- </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>dihydroxyandrost-4-en-3-one), </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>17[beta]-hydroxy-(5[alpha]-androstan-3-one), </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5[alpha]-androst-2-eno[3,2-c]-pyrazole), </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lviii) stenbolone (17[beta]-hydroxy-2-methyl- </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5[alpha]-androst-1-en-3-one), </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lix) testolactone (13-hydroxy-3-oxo-13,17- </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>secoandrosta-1,4-dien-17-oic </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>acid lactone), </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lx) testosterone (17[beta]-hydroxyandrost- </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>4-en-3-one), </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 31 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lxi) tetrahydrogestrinone (13[beta], 17[alpha]- </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>diethyl-17[beta]-hydroxygon- </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>4,9,11-trien-3-one), </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(lxii) trenbolone (17[beta]-hydroxyestr-4,9, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>11-trien-3-one). </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Any person who is otherwise lawfully in possession of an </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>anabolic steroid, or who otherwise lawfully manufactures, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>distributes, dispenses, delivers, or possesses with intent to </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>deliver an anabolic steroid, which anabolic steroid is </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>expressly intended for and lawfully allowed to be administered </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>through implants to livestock or other nonhuman species, and </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>which is approved by the Secretary of Health and Human </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Services for such administration, and which the person intends </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>to administer or have administered through such implants, </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>shall not be considered to be in unauthorized possession or to </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>unlawfully manufacture, distribute, dispense, deliver, or </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>possess with intent to deliver such anabolic steroid for </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>purposes of this Act. </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) "Administration" means the Drug Enforcement </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Administration, United States Department of Justice, or its </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>successor agency. </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d-5) "Clinical Director, Prescription Monitoring Program" </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>means a Department of Human Services administrative employee </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>licensed to either prescribe or dispense controlled substances </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>who shall run the clinical aspects of the Department of Human </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>Services Prescription Monitoring Program and its Prescription </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 32 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Information Library.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d-10) "Compounding" means the preparation and mixing of </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>components, excluding flavorings, (1) as the result of a </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>prescriber's prescription drug order or initiative based on </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>the prescriber-patient-pharmacist relationship in the course </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>of professional practice or (2) for the purpose of, or </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>incident to, research, teaching, or chemical analysis and not </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>for sale or dispensing. "Compounding" includes the preparation </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>of drugs or devices in anticipation of receiving prescription </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>drug orders based on routine, regularly observed dispensing </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>patterns. Commercially available products may be compounded </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>for dispensing to individual patients only if both of the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>following conditions are met: (i) the commercial product is </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>not reasonably available from normal distribution channels in </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>a timely manner to meet the patient's needs and (ii) the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>prescribing practitioner has requested that the drug be </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>compounded. </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) "Control" means to add a drug or other substance, or </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>immediate precursor, to a Schedule whether by transfer from </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>another Schedule or otherwise. </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) "Controlled Substance" means (i) a drug, substance, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>immediate precursor, or synthetic drug in the Schedules of </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>Article II of this Act or (ii) a drug or other substance, or </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>immediate precursor, designated as a controlled substance by </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>the Department through administrative rule. The term does not </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>include distilled spirits, wine, malt beverages, or tobacco, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 33 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>as those terms are defined or used in the Liquor Control Act of </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>1934 and the Tobacco Products Tax Act of 1995. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f-5) "Controlled substance analog" means a substance:</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the chemical structure of which is substantially </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>similar to the chemical structure of a controlled </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>substance in Schedule I or II;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) which has a stimulant, depressant, or </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>hallucinogenic effect on the central nervous system that </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>is substantially similar to or greater than the stimulant, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>depressant, or hallucinogenic effect on the central </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>nervous system of a controlled substance in Schedule I or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>II; or</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) with respect to a particular person, which such </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>person represents or intends to have a stimulant, </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>depressant, or hallucinogenic effect on the central </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>nervous system that is substantially similar to or greater </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>than the stimulant, depressant, or hallucinogenic effect </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>on the central nervous system of a controlled substance in </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>Schedule I or II. </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) "Counterfeit substance" means a controlled substance, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>which, or the container or labeling of which, without </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>authorization bears the trademark, trade name, or other </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>identifying mark, imprint, number or device, or any likeness </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>thereof, of a manufacturer, distributor, or dispenser other </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>than the person who in fact manufactured, distributed, or </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>dispensed the substance. </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 34 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) "Deliver" or "delivery" means the actual, constructive </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>or attempted transfer of possession of a controlled substance, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>with or without consideration, whether or not there is an </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>agency relationship. "Deliver" or "delivery" does not include </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>the donation of drugs to the extent permitted under the </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>Illinois Drug Reuse Opportunity Program Act. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) "Department" means the Illinois Department of Human </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>Services (as successor to the Department of Alcoholism and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Substance Abuse) or its successor agency. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(j) (Blank). </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(k) "Department of Corrections" means the Department of </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Corrections of the State of Illinois or its successor agency. </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(l) "Department of Financial and Professional Regulation" </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>means the Department of Financial and Professional Regulation </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>of the State of Illinois or its successor agency. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(m) "Depressant" means any drug that (i) causes an overall </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>depression of central nervous system functions, (ii) causes </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>impaired consciousness and awareness, and (iii) can be </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>habit-forming or lead to a substance misuse or substance use </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>disorder, including, but not limited to, alcohol, cannabis and </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>its active principles and their analogs, benzodiazepines and </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>their analogs, barbiturates and their analogs, opioids </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>(natural and synthetic) and their analogs, and chloral hydrate </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>and similar sedative hypnotics. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(n) (Blank). </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(o) "Director" means the Director of the Illinois State </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 35 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Police or his or her designated agents. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(p) "Dispense" means to deliver a controlled substance to </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>an ultimate user or research subject by or pursuant to the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>lawful order of a prescriber, including the prescribing, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>administering, packaging, labeling, or compounding necessary </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>to prepare the substance for that delivery. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(q) "Dispenser" means a practitioner who dispenses. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(r) "Distribute" means to deliver, other than by </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>administering or dispensing, a controlled substance. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(s) "Distributor" means a person who distributes. </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t) "Drug" means (1) substances recognized as drugs in the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>official United States Pharmacopoeia, Official Homeopathic </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Pharmacopoeia of the United States, or official National </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>Formulary, or any supplement to any of them; (2) substances </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>intended for use in diagnosis, cure, mitigation, treatment, or </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>prevention of disease in man or animals; (3) substances (other </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>than food) intended to affect the structure of any function of </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>the body of man or animals and (4) substances intended for use </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>as a component of any article specified in clause (1), (2), or </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>(3) of this subsection. It does not include devices or their </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>components, parts, or accessories. </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-3) "Electronic health record" or "EHR" means an </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>electronic record of health-related information on an </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>individual that is created, gathered, managed, and consulted </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>by authorized health care clinicians and staff. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-3.5) "Electronic health record system" or "EHR system" </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 36 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>means any computer-based system or combination of federally </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>certified Health IT Modules (defined at 42 CFR 170.102 or its </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>successor) used as a repository for electronic health records </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>and accessed or updated by a prescriber or authorized </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>surrogate in the ordinary course of his or her medical </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>practice. For purposes of connecting to the Prescription </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Information Library maintained by the Bureau of Pharmacy and </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>Clinical Support Systems or its successor, an EHR system may </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>connect to the Prescription Information Library directly or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>through all or part of a computer program or system that is a </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>federally certified Health IT Module maintained by a third </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>party and used by the EHR system to secure access to the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>database.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-4) "Emergency medical services personnel" has the </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>meaning ascribed to it in the Emergency Medical Services (EMS) </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Systems Act.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-5) "Euthanasia agency" means an entity certified by the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>Department of Financial and Professional Regulation for the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>purpose of animal euthanasia that holds an animal control </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>facility license or animal shelter license under the Animal </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>Welfare Act. A euthanasia agency is authorized to purchase, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>store, possess, and utilize Schedule II nonnarcotic and </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>Schedule III nonnarcotic drugs for the sole purpose of animal </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>euthanasia. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(t-10) "Euthanasia drugs" means Schedule II or Schedule </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>III substances (nonnarcotic controlled substances) that are </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 37 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>used by a euthanasia agency for the purpose of animal </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>euthanasia. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u) "Good faith" means the prescribing or dispensing of a </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>controlled substance by a practitioner in the regular course </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>of professional treatment to or for any person who is under his </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or her treatment for a pathology or condition other than that </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>individual's physical or psychological dependence upon a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>controlled substance, except as provided herein: and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>application of the term to a pharmacist shall mean the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>dispensing of a controlled substance pursuant to the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>prescriber's order which in the professional judgment of the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>pharmacist is lawful. The pharmacist shall be guided by </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>accepted professional standards, including, but not limited </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>to, the following, in making the judgment: </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) lack of consistency of prescriber-patient </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>relationship, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) frequency of prescriptions for same drug by one </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>prescriber for large numbers of patients, </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) quantities beyond those normally prescribed, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) unusual dosages (recognizing that there may be </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>clinical circumstances where more or less than the usual </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>dose may be used legitimately), </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) unusual geographic distances between patient, </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>pharmacist and prescriber, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) consistent prescribing of habit-forming drugs. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u-0.5) "Hallucinogen" means a drug that causes markedly </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 38 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>altered sensory perception leading to hallucinations of any </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>type. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u-1) "Home infusion services" means services provided by </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>a pharmacy in compounding solutions for direct administration </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>to a patient in a private residence, long-term care facility, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or hospice setting by means of parenteral, intravenous, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>intramuscular, subcutaneous, or intraspinal infusion. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(u-5) "Illinois State Police" means the Illinois State </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Police or its successor agency. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(v) "Immediate precursor" means a substance: </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) which the Department has found to be and by rule </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>designated as being a principal compound used, or produced </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>primarily for use, in the manufacture of a controlled </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>substance; </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) which is an immediate chemical intermediary used </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>or likely to be used in the manufacture of such controlled </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>substance; and </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the control of which is necessary to prevent, </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>curtail or limit the manufacture of such controlled </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>substance. </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(w) "Instructional activities" means the acts of teaching, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>educating or instructing by practitioners using controlled </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>substances within educational facilities approved by the State </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>Board of Education or its successor agency. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(w-1) "Isomer" means optical isomer, unless specifically </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><u><code>detailed in this Act.</code></u><code> </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 39 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(x) "Local authorities" means a duly organized State, </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>County or Municipal peace unit or police force. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(y) "Look-alike substance" means a substance, other than a </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>controlled substance which (1) by overall dosage unit </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>appearance, including shape, color, size, markings or lack </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>thereof, taste, consistency, or any other identifying physical </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>characteristic of the substance, would lead a reasonable </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>person to believe that the substance is a controlled </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>substance, or (2) is expressly or impliedly represented to be </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>a controlled substance or is distributed under circumstances </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>which would lead a reasonable person to believe that the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>substance is a controlled substance. For the purpose of </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>determining whether the representations made or the </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>circumstances of the distribution would lead a reasonable </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>person to believe the substance to be a controlled substance </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>under this clause (2) of subsection (y), the court or other </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>authority may consider the following factors in addition to </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>any other factor that may be relevant: </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(a) statements made by the owner or person in control </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>of the substance concerning its nature, use or effect; </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(b) statements made to the buyer or recipient that the </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>substance may be resold for profit; </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(c) whether the substance is packaged in a manner </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>normally used for the illegal distribution of controlled </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>substances; </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(d) whether the distribution or attempted distribution </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 40 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>included an exchange of or demand for money or other </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>property as consideration, and whether the amount of the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>consideration was substantially greater than the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>reasonable retail market value of the substance. </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Clause (1) of this subsection (y) shall not apply to a </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>noncontrolled substance in its finished dosage form that was </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>initially introduced into commerce prior to the initial </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>introduction into commerce of a controlled substance in its </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>finished dosage form which it may substantially resemble. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Nothing in this subsection (y) prohibits the dispensing or </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>distributing of noncontrolled substances by persons authorized </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>to dispense and distribute controlled substances under this </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Act, provided that such action would be deemed to be carried </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>out in good faith under subsection (u) if the substances </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>involved were controlled substances. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Nothing in this subsection (y) or in this Act prohibits </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>the manufacture, preparation, propagation, compounding, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>processing, packaging, advertising or distribution of a drug </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>or drugs by any person registered pursuant to Section 510 of </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360). </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(y-1) "Mail-order pharmacy" means a pharmacy that is </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>located in a state of the United States that delivers, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>dispenses or distributes, through the United States Postal </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>Service or other common carrier, to Illinois residents, any </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>substance which requires a prescription. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z) "Manufacture" means the production, preparation, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 41 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>propagation, compounding, conversion or processing of a </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>controlled substance other than methamphetamine, either </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>directly or indirectly, by extraction from substances of </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>natural origin, or independently by means of chemical </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>synthesis, or by a combination of extraction and chemical </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>synthesis, and includes any packaging or repackaging of the </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>substance or labeling of its container, except that this term </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>does not include: </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) by an ultimate user, the preparation or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>compounding of a controlled substance for his or her own </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>use; </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) by a practitioner, or his or her authorized agent </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>under his or her supervision, the preparation, </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>compounding, packaging, or labeling of a controlled </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>substance: </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(a) as an incident to his or her administering or </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <code>dispensing of a controlled substance in the course of </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <code>his or her professional practice; or </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(b) as an incident to lawful research, teaching or </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <code>chemical analysis and not for sale; or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the packaging, repackaging, or labeling of drugs </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>only to the extent permitted under the Illinois Drug Reuse </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>Opportunity Program Act. </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z-1) (Blank). </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z-5) "Medication shopping" means the conduct prohibited </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>under subsection (a) of Section 314.5 of this Act.</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 42 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(z-10) "Mid-level practitioner" means (i) a physician </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>assistant who has been delegated authority to prescribe </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>through a written delegation of authority by a physician </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>licensed to practice medicine in all of its branches, in </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 7.5 of the Physician Assistant </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>Practice Act of 1987, (ii) an advanced practice registered </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>nurse who has been delegated authority to prescribe through a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>written delegation of authority by a physician licensed to </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>practice medicine in all of its branches or by a podiatric </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>physician, in accordance with Section 65-40 of the Nurse </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Practice Act, (iii) an advanced practice registered nurse </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>certified as a nurse practitioner, nurse midwife, or clinical </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>nurse specialist who has been granted authority to prescribe </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>by a hospital affiliate in accordance with Section 65-45 of </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>the Nurse Practice Act, (iv) an animal euthanasia agency, or </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>(v) a prescribing psychologist. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(aa) "Narcotic drug" means any of the following, whether </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>produced directly or indirectly by extraction from substances </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>of vegetable origin, or independently by means of chemical </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>synthesis, or by a combination of extraction and chemical </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>synthesis: </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) opium, opiates, derivatives of opium and opiates, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>including their isomers, esters, ethers, salts, and salts </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>of isomers, esters, and ethers, whenever the existence of </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>such isomers, esters, ethers, and salts is possible within </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>the specific chemical designation; however the term </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 43 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>"narcotic drug" does not include the isoquinoline </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>alkaloids of opium; </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) (blank); </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) opium poppy and poppy straw; </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) coca leaves, except coca leaves and extracts of </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>coca leaves from which substantially all of the cocaine </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>and ecgonine, and their isomers, derivatives and salts, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>have been removed; </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) cocaine, its salts, optical and geometric isomers, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>and salts of isomers;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) ecgonine, its derivatives, their salts, isomers, </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>and salts of isomers;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) any compound, mixture, or preparation which </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>contains any quantity of any of the substances referred to </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>in subparagraphs (1) through (6). </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(bb) "Nurse" means a registered nurse licensed under the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act. </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(cc) (Blank). </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(dd) "Opiate" means a drug derived from or related to </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>opium. </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ee) "Opium poppy" means the plant of the species Papaver </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>somniferum L., except its seeds. </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ee-5) "Oral dosage" means a tablet, capsule, elixir, or </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>solution or other liquid form of medication intended for </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>administration by mouth, but the term does not include a form </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>of medication intended for buccal, sublingual, or transmucosal </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 44 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>administration. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ff) "Parole and Pardon Board" means the Parole and Pardon </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Board of the State of Illinois or its successor agency. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(gg) "Person" means any individual, corporation, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>mail-order pharmacy, government or governmental subdivision or </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>agency, business trust, estate, trust, partnership or </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>association, or any other entity. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(hh) "Pharmacist" means any person who holds a license or </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>certificate of registration as a registered pharmacist, a </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>local registered pharmacist or a registered assistant </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>pharmacist under the Pharmacy Practice Act. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii) "Pharmacy" means any store, ship or other place in </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>which pharmacy is authorized to be practiced under the </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>Pharmacy Practice Act. </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii-5) "Pharmacy shopping" means the conduct prohibited </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>under subsection (b) of Section 314.5 of this Act.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ii-10) "Physician" (except when the context otherwise </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>requires) means a person licensed to practice medicine in all </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>of its branches. </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(jj) "Poppy straw" means all parts, except the seeds, of </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>the opium poppy, after mowing. </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(kk) "Practitioner" means a physician licensed to practice </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>medicine in all its branches, dentist, optometrist, podiatric </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>physician, veterinarian, scientific investigator, pharmacist, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>physician assistant, advanced practice registered nurse, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>licensed practical nurse, registered nurse, emergency medical </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 45 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>services personnel, hospital, laboratory, or pharmacy, or </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>other person licensed, registered, or otherwise lawfully </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>permitted by the United States or this State to distribute, </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>dispense, conduct research with respect to, administer or use </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>in teaching or chemical analysis, a controlled substance in </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>the course of professional practice or research. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ll) "Pre-printed prescription" means a written </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>prescription upon which the designated drug has been indicated </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>prior to the time of issuance; the term does not mean a written </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>prescription that is individually generated by machine or </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>computer in the prescriber's office. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(mm) "Prescriber" means a physician licensed to practice </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>medicine in all its branches, dentist, optometrist, </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>prescribing psychologist licensed under Section 4.2 of the </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>Clinical Psychologist Licensing Act with prescriptive </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>authority delegated under Section 4.3 of the Clinical </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Psychologist Licensing Act, podiatric physician, or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>veterinarian who issues a prescription, a physician assistant </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>who issues a prescription for a controlled substance in </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 303.05, a written delegation, and a </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>written collaborative agreement required under Section 7.5 of </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>the Physician Assistant Practice Act of 1987, an advanced </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>practice registered nurse with prescriptive authority </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>delegated under Section 65-40 of the Nurse Practice Act and in </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 303.05, a written delegation, and a </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>written collaborative agreement under Section 65-35 of the </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 46 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act, an advanced practice registered nurse </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>certified as a nurse practitioner, nurse midwife, or clinical </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>nurse specialist who has been granted authority to prescribe </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>by a hospital affiliate in accordance with Section 65-45 of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>the Nurse Practice Act and in accordance with Section 303.05, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>or an advanced practice registered nurse certified as a nurse </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>practitioner, nurse midwife, or clinical nurse specialist who </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>has full practice authority pursuant to Section 65-43 of the </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(nn) "Prescription" means a written, facsimile, or oral </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>order, or an electronic order that complies with applicable </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>federal requirements, of a physician licensed to practice </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>medicine in all its branches, dentist, podiatric physician or </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>veterinarian for any controlled substance, of an optometrist </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>in accordance with Section 15.1 of the Illinois Optometric </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Practice Act of 1987, of a prescribing psychologist licensed </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>under Section 4.2 of the Clinical Psychologist Licensing Act </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>with prescriptive authority delegated under Section 4.3 of the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>Clinical Psychologist Licensing Act, of a physician assistant </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>for a controlled substance in accordance with Section 303.05, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>a written delegation, and a written collaborative agreement </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>required under Section 7.5 of the Physician Assistant Practice </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>Act of 1987, of an advanced practice registered nurse with </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>prescriptive authority delegated under Section 65-40 of the </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act who issues a prescription for a controlled </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>substance in accordance with Section 303.05, a written </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 47 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>delegation, and a written collaborative agreement under </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>Section 65-35 of the Nurse Practice Act, of an advanced </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>practice registered nurse certified as a nurse practitioner, </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>nurse midwife, or clinical nurse specialist who has been </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>granted authority to prescribe by a hospital affiliate in </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 65-45 of the Nurse Practice Act and in </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 303.05 when required by law, or of an </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>advanced practice registered nurse certified as a nurse </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>practitioner, nurse midwife, or clinical nurse specialist who </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>has full practice authority pursuant to Section 65-43 of the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Nurse Practice Act. </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(nn-5) "Prescription Information Library" (PIL) means an </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>electronic library that contains reported controlled substance </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>data.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(nn-10) "Prescription Monitoring Program" (PMP) means the </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>entity that collects, tracks, and stores reported data on </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>controlled substances and select drugs pursuant to Section </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>316. </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(oo) "Production" or "produce" means manufacture, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>planting, cultivating, growing, or harvesting of a controlled </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>substance other than methamphetamine. </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(pp) "Registrant" means every person who is required to </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>register under Section 302 of this Act. </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(qq) "Registry number" means the number assigned to each </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>person authorized to handle controlled substances under the </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>laws of the United States and of this State. </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 48 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(qq-5) "Secretary" means, as the context requires, either </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>the Secretary of the Department or the Secretary of the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Department of Financial and Professional Regulation, and the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>Secretary's designated agents. </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(rr) "State" includes the State of Illinois and any state, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>district, commonwealth, territory, insular possession thereof, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>and any area subject to the legal authority of the United </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>States of America. </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(rr-5) "Stimulant" means any drug that (i) causes an </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>overall excitation of central nervous system functions, (ii) </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>causes impaired consciousness and awareness, and (iii) can be </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>habit-forming or lead to a substance use disorder, including, </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>but not limited to, amphetamines and their analogs, </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>methylphenidate and its analogs, cocaine, and phencyclidine </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>and its analogs. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(rr-10) "Synthetic drug" includes, but is not limited to, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>any synthetic cannabinoids or piperazines or any synthetic </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>cathinones as provided for in Schedule I. </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(ss) "Ultimate user" means a person who lawfully possesses </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>a controlled substance for his or her own use or for the use of </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>a member of his or her household or for administering to an </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>animal owned by him or her or by a member of his or her </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>household. </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)</code><br> </td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 49 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(720 ILCS 570/204)</code><code>  </code><code>(from Ch. 56 1/2, par. 1204)</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 204. </code><code>(a) The controlled substances listed in this </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Section are included in Schedule I.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>another schedule, any of the following opiates, including </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>their isomers, esters, ethers, salts, and salts of isomers, </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>esters, and ethers, whenever the existence of such isomers, </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>esters, ethers and salts is possible within the specific </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>chemical designation:</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Acetylmethadol;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Acetyl-alpha-methylfentanyl</code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-[1-(1-methyl-2-phenethyl)-</code></strike><code>
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidinyl]-N-phenylacetamide);</code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Allylprodine;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Alphacetylmethadol, except
</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>levo-alphacetylmethadol (also known as levo-alpha-
</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>acetylmethadol, levomethadyl acetate, or LAAM);</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Alphameprodine;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Alphamethadol;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Alpha-methylfentanyl
</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>propanilido) piperidine;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Alpha-methylthiofentanyl</code></strike><code>
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-[1-methyl-2-(2-thienyl)ethyl-</code></strike><code>
</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidinyl]-N-phenylpropanamide);</code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 50 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7.1) PEPAP
</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Benzethidine;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Betacetylmethadol;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Beta-hydroxyfentanyl</code></strike><code>
</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-[1-(2-hydroxy-2-phenethyl)-</code></strike><code>
</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidinyl]-N-phenylpropanamide);</code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Betameprodine;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Betamethadol;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Betaprodine;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(12.1) Brorphine;</code></u><code> </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Clonitazene;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Dextromoramide;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Diampromide;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Diethylthiambutene;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(17) Difenoxin;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(18) Dimenoxadol;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(19) Dimepheptanol;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(20) Dimethylthiambutene;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(21) Dioxaphetylbutyrate;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(22) Dipipanone;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(23) Ethylmethylthiambutene;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(24) Etonitazene;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(25) Etoxeridine;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(25.1) Flunitazene;</code></u><code> </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 51 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(26) Furethidine;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(27) Hydroxpethidine;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(27.1) Isotonitazene;</code></u><code> </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(28) Ketobemidone;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(29) Levomoramide;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(30) Levophenacylmorphan;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(31) </code><u><code>(Blank);</code></u><code> </code><strike><code>3-Methylfentanyl</code></strike><code>
</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-[3-methyl-1-(2-phenylethyl)-</code></strike><code>
</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidyl]-N-phenylpropanamide);</code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(31.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>3-Methylthiofentanyl</code></strike><code>
</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-[(3-methyl-1-(2-thienyl)ethyl-</code></strike><code>
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidinyl]-N-phenylpropanamide);</code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(31.2) Metonitazene;</code></u><code> </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(32) Morpheridine;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(33) Noracymethadol;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(34) Norlevorphanol;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(35) Normethadone;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(36) Norpipanone;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(36.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Para-fluorofentanyl</code></strike><code>
</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-</code></strike><code>
</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidinyl]propanamide);</code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(37) Phenadoxone;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(38) Phenampromide;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(39) Phenomorphan;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(40) Phenoperidine;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(41) Piritramide;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 52 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(42) Proheptazine;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(43) Properidine;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(44) Propiram;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(45) Racemoramide;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(45.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Thiofentanyl</code></strike><code>
</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>(N-phenyl-N-[1-(2-thienyl)ethyl-</code></strike><code>
</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>4-piperidinyl]-propanamide);</code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(46) Tilidine;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(47) Trimeperidine;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(48) </code><u><code>(Blank);</code></u><code> </code><strike><code>Beta-hydroxy-3-methylfentanyl (other </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><strike><code>name:</code></strike><code>
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-</code></strike><code>
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><strike><code>N-phenylpropanamide);</code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(49) </code><u><code>(Blank);</code></u><code> </code><strike><code>Furanyl fentanyl (FU-F);</code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(50) </code><u><code>(Blank);</code></u><code> </code><strike><code>Butyryl fentanyl;</code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(51) </code><u><code>(Blank);</code></u><code> </code><strike><code>Valeryl fentanyl;</code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(52) </code><u><code>(Blank);</code></u><code> </code><strike><code>Acetyl fentanyl;</code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53) </code><u><code>(Blank);</code></u><code> </code><strike><code>Beta-hydroxy-thiofentanyl;</code></strike><code> </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(54) 3,4-dichloro-N-[2-
</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(dimethylamino)cyclohexyl]-N-
</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>methylbenzamide (U-47700); </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(55) 4-chloro-N-[1-[2-
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(4-nitrophenyl)ethyl]-2-piperidinylidene]-
</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>benzenesulfonamide (W-18); </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(56) 4-chloro-N-[1-(2-phenylethyl)
</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>-2-piperidinylidene]-benzenesulfonamide (W-15); </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 53 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(57) </code><u><code>(Blank).</code></u><code> </code><strike><code>acrylfentanyl (acryloylfentanyl).</code></strike><code> </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>another schedule, any of the following opium derivatives, its </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>salts, isomers and salts of isomers, whenever the existence of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>such salts, isomers and salts of isomers is possible within </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>the specific chemical designation:</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Acetorphine;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Acetyldihydrocodeine;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Benzylmorphine;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Codeine methylbromide;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Codeine-N-Oxide;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Cyprenorphine;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Desomorphine;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Diacetyldihydromorphine (Dihydroheroin);</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Dihydromorphine;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Drotebanol;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Etorphine (except hydrochloride salt);</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Heroin;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Hydromorphinol;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Methyldesorphine;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Methyldihydromorphine;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Morphine methylbromide;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(17) Morphine methylsulfonate;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(18) Morphine-N-Oxide;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(19) Myrophine;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(20) Nicocodeine;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 54 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(21) Nicomorphine;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(22) Normorphine;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(23) Pholcodine;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(24) Thebacon.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>hallucinogenic substances, or which contains any of its salts, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>isomers and salts of isomers, whenever the existence of such </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>salts, isomers, and salts of isomers is possible within the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>specific chemical designation (for the purposes of this </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>paragraph only, the term "isomer" includes the optical, </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>position and geometric isomers):</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) 3,4-methylenedioxyamphetamine
</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    (alpha-methyl,3,4-methylenedioxyphenethylamine,
</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    methylenedioxyamphetamine, MDA);</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1.1) Alpha-ethyltryptamine</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(some trade or other names: etryptamine;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>MONASE; alpha-ethyl-1H-indole-3-ethanamine;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>3-(2-aminobutyl)indole; a-ET; and AET);</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) 3,4-methylenedioxymethamphetamine (MDMA);</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2.1) 3,4-methylenedioxy-N-ethylamphetamine
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    (also known as: N-ethyl-alpha-methyl-
</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    and MDEA);</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2.2) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-Benzylpiperazine (BZP);</code></strike><code> </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 55 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2.2-1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Trifluoromethylphenylpiperazine </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>(TFMPP);</code></strike><code> </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) 3,4,5-trimethoxyamphetamine (TMA);</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) (Blank);</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Diethyltryptamine (DET);</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Dimethyltryptamine (DMT);</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7.1) 5-Methoxy-diallyltryptamine; </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Ibogaine  (some trade and other names:
</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>indole; Tabernanthe iboga);</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Lysergic acid diethylamide;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10.1) Salvinorin A; </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10.5) Salvia divinorum (meaning all parts of the </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>plant presently classified botanically as Salvia </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>divinorum, whether growing or not, the seeds thereof, any </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>extract from any part of that plant, and every compound, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>manufacture, salts, isomers, and salts of isomers whenever </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>the existence of such salts, isomers, and salts of isomers </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>is possible within the specific chemical designation, </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>derivative, mixture, or preparation of that plant, its </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>seeds or extracts); </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) 3,4,5-trimethoxyphenethylamine (Mescaline);</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Peyote (meaning all parts of the plant presently </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 56 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>classified botanically as Lophophora williamsii Lemaire, </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>whether growing or not, the seeds thereof, any extract </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>from any part of that plant, and every compound, </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>manufacture, salts, derivative, mixture, or preparation of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>that plant, its seeds or extracts);</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) N-ethyl-3-piperidyl benzilate (JB 318);</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) N-methyl-3-piperidyl benzilate;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(also known as N-hydroxy-alpha-methyl-
</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Parahexyl; some trade or other names:
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    dibenzo (b,d) pyran; Synhexyl;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Psilocybin;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(17) Psilocyn;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(18) Alpha-methyltryptamine (AMT);</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(19) 2,5-dimethoxyamphetamine
</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(20) 4-bromo-2,5-dimethoxyamphetamine
</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-bromo-2,5-DMA);</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    Some trade or other names: 2-(4-bromo-
</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    2,5-dimethoxyphenyl)-1-aminoethane;
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    alpha-desmethyl DOB, 2CB, Nexus;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(21) 4-methoxyamphetamine
</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 57 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(4-methoxy-alpha-methylphenethylamine;
</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>paramethoxyamphetamine; PMA);</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(22) (Blank);</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(23) Ethylamine analog of phencyclidine.
</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    Some trade or other names:
</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    N-ethyl-1-phenylcyclohexylamine,
</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    (1-phenylcyclohexyl) ethylamine,
</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(24) Pyrrolidine analog of phencyclidine. Some trade </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>PHP;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(25) 5-methoxy-3,4-methylenedioxy-amphetamine;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(26) 2,5-dimethoxy-4-ethylamphetamine
</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(another name: DOET);</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(another name: TCPy);</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(28) (Blank);</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(29) Thiophene analog of phencyclidine (some trade
</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    2-thienyl analog of phencyclidine; TPCP; TCP);</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(29.1) Benzothiophene analog of phencyclidine. Some </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: BTCP or benocyclidine;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(29.2) 3-Methoxyphencyclidine (3-MeO-PCP); </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(30) Bufotenine (some trade or other names:
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>3-(2-dimethylaminoethyl)-5-indolol;
</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 58 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>5-hydroxy-N,N-dimethyltryptamine;
</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>N,N-dimethylserotonin; mappine);</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(31) (Blank);  </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(32) (Blank);  </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(33) (Blank);  </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(34) (Blank); </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(34.5) (Blank);  </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(2-methyloctan-2-yl)-6a,7, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>10,10a-tetrahydrobenzo[c]chromen-1-ol</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names: HU-210; </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>tetrahydrobenzo[c]chromen-1-ol, its isomers,  </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>salts, and salts of isomers; Some trade or other  </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>names: HU-210, Dexanabinol; </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>6,6-dimethyl-3-(2-methyloctan-2-yl)- </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names: HU-211;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(37) (Blank); </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(38) (Blank); </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(39) (Blank); </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(40) (Blank); </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(41) (Blank); </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(42) </code><u><code>(Blank);</code></u><code> </code><strike><code>Any compound structurally derived from </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 59 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>3-(1-naphthoyl)indole or </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>1H-indol-3-yl-(1-naphthyl)methane by substitution at the </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl whether or not further substituted </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>in the indole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted in the naphthyl ring to any extent. Examples </code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <strike><code>of this structural class include, but are not limited to, </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;</code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(43) </code><u><code>(Blank);</code></u><code> </code><strike><code>Any compound structurally derived from </code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <strike><code>3-(1-naphthoyl)pyrrole by substitution at the nitrogen </code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <strike><code>atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <strike><code>in the pyrrole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted in the naphthyl ring to any extent. Examples </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <strike><code>of this structural class include, but are not limited to, </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;</code></strike><code> </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(44) </code><u><code>(Blank);</code></u><code> </code><strike><code>Any compound structurally derived from </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>1-(1-naphthylmethyl)indene by substitution at the </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>3-position of the indene ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl whether or not further substituted </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 60 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>in the indene ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted in the naphthyl ring to any extent. Examples </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>of this structural class include, but are not limited to, </code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>JWH-176;</code></strike><code> </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(45) </code><u><code>(Blank);</code></u><code> </code><strike><code>Any compound structurally derived from </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>3-phenylacetylindole by substitution at the nitrogen atom </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>of the indole ring with alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <strike><code>in the indole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted in the phenyl ring to any extent. Examples of </code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <strike><code>this structural class include, but are not limited to, </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>JWH-167, JWH-250, JWH-251, and RCS-8;</code></strike><code> </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(46) </code><u><code>(Blank);</code></u><code> </code><strike><code>Any compound structurally derived from </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(3-hydroxycyclohexyl)phenol by substitution at the </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <strike><code>5-position of the phenolic ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not substituted in the </code></strike></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <strike><code>cyclohexyl ring to any extent. Examples of this structural </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>class include, but are not limited to, CP 47, 497 and its </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>C8 homologue (cannabicyclohexanol);</code></strike><code> </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(46.1) </code><u><code>(Blank);</code></u><code> </code><strike><code>Any compound structurally derived from </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>3-(benzoyl) indole with substitution at the nitrogen atom </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>of the indole ring by an alkyl, haloalkyl, alkenyl, </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 61 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl group whether or not further </code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted in the indole ring to any extent and whether </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>or not substituted in the phenyl ring to any extent. </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>Examples of this structural class include, but are not </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>48,098), and RCS-4;</code></strike><code> </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(47) (Blank); </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(48) (Blank); </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(49) (Blank); </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(50) (Blank); </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(51) (Blank); </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(52) (Blank); </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>Some trade or other names: 2C-T-7; </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: 2C-E; </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: 2C-D; </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: 2C-C; </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>or other names: 2C-I; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: 2C-T-2; </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 62 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>Some trade or other names: 2C-T-4; </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.7) 2,5-dimethoxyphenethylamine. Some trade or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>other names: 2C-H; </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: 2C-N; </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>trade or other names: 2C-P; </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>Some trade or other names: 2C-G; </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(53.11) The N-(2-methoxybenzyl) derivative of any 2C </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>phenethylamine referred to in subparagraphs (20.1), (53), </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>(53.8), (53.9), and (53.10) including, but not limited to, </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>25I-NBOMe and 25C-NBOMe; </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(54) 5-Methoxy-N,N-diisopropyltryptamine; </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(55) (Blank); </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(56) (Blank); </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(57) (Blank); </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(58) (Blank); </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(59) </code><u><code>(Blank);</code></u><code> </code><strike><code>3-cyclopropoylindole with substitution </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>at the nitrogen atom of the indole ring by alkyl, </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>aryl halide, alkyl aryl halide, </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 63 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the cyclopropyl ring to any extent: </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>including, but not limited to, XLR11, UR144, FUB-144;</code></strike><code> </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(60) </code><u><code>(Blank);</code></u><code> </code><strike><code>3-adamantoylindole with substitution at </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>the nitrogen atom of the indole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the adamantyl ring to any extent: </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <strike><code>including, but not limited to, AB-001;</code></strike><code> </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(61) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(adamantyl)-indole-3-carboxamide with </code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <strike><code>substitution at the nitrogen atom of the indole ring by </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the adamantyl ring to any extent: </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>including, but not limited to, APICA/2NE-1, STS-135;</code></strike><code> </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(62) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(adamantyl)-indazole-3-carboxamide </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>with substitution at a nitrogen atom of the indazole ring </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 64 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the adamantyl ring to any extent: </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>including, but not limited to, AKB48, 5F-AKB48;</code></strike><code> </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(63) </code><u><code>(Blank);</code></u><code> </code><strike><code>1H-indole-3-carboxylic acid </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>8-quinolinyl ester with substitution at the nitrogen atom </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>of the indole ring by alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the quinoline ring to any extent: </code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <strike><code>including, but not limited to, PB22, 5F-PB22, FUB-PB-22;</code></strike><code> </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(64) </code><u><code>(Blank);</code></u><code> </code><strike><code>3-(1-naphthoyl)indazole with </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>substitution at the nitrogen atom of the indazole ring by </code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <strike><code>1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the naphthyl ring to any extent: including, </code></strike></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <strike><code>but not limited to, THJ-018, THJ-2201;</code></strike><code> </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(65) </code><u><code>(Blank);</code></u><code> </code><strike><code>2-(1-naphthoyl)benzimidazole with </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>substitution at the nitrogen atom of the benzimidazole </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 65 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>on the benzimidazole ring to any extent, whether or not </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>substituted on the naphthyl ring to any extent: including, </code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>but not limited to, FUBIMINA;</code></strike><code> </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(66) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(1-amino-3-methyl-1-oxobutan-2-yl)- </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>1H-indazole-3-carboxamide with substitution on the </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indazole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;</code></strike><code> </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(67) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(1-amino-3,3-dimethyl-1-oxobutan- </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>2-yl)-1H-indazole-3-carboxamide with substitution on the </code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indazole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, ADB-PINACA, ADB-FUBINACA;</code></strike><code> </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(68) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(1-amino-3,3-dimethyl-1-oxobutan- </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>2-yl)-1H-indole-3-carboxamide with substitution on the </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 66 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, ADBICA, 5F-ADBICA;</code></strike><code> </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(69) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(1-amino-3-methyl-1-oxobutan-2 -</code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>yl)-1H-indole-3-carboxamide with substitution on the </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, ABICA, 5F-ABICA;</code></strike><code> </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(70) </code><u><code>(Blank);</code></u><code> </code><strike><code>Methyl 2-(1H-indazole-3-carboxamido)-3- </code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <strike><code>methylbutanoate with substitution on the nitrogen atom of </code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <strike><code>the indazole ring by alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, AMB, 5F-AMB;</code></strike><code> </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(71) </code><u><code>(Blank);</code></u><code> </code><strike><code>Methyl 2-(1H-indazole-3-carboxamido)- </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>3,3-dimethylbutanoate with substitution on the nitrogen </code></strike></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <strike><code>atom of the indazole ring by alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;</code></strike><code> </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 67 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(72) </code><u><code>(Blank);</code></u><code> </code><strike><code>Methyl 2-(1H-indole-3-carboxamido)-3- </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>methylbutanoate with substitution on the nitrogen atom of </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>the indole ring by alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, MMB018, MMB2201, and AMB-CHMICA;</code></strike><code> </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(73) </code><u><code>(Blank);</code></u><code> </code><strike><code>Methyl 2-(1H-indole-3-carboxamido)-3,3- </code></strike></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <strike><code>dimethylbutanoate with substitution on the nitrogen atom </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <strike><code>of the indole ring by alkyl, haloalkyl, alkenyl, </code></strike></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <strike><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl </code></strike></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <strike><code>halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, MDMB-CHMICA;</code></strike><code> </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(74) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(1-Amino-1-oxo-3-phenylpropan- </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <strike><code>2-yl)-1H-indazole-3-carboxamide with substitution on the </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indazole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any </code></strike><strike><code>    </code></strike><strike><code>extent: including, but not </code></strike></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;</code></strike><code> </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(75) </code><u><code>(Blank);</code></u><code> </code><strike><code>N-(1-Amino-1-oxo-3-phenylpropan- </code></strike></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <strike><code>2-yl)-1H-indole-3-carboxamide with substitution on the </code></strike></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 68 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <strike><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></strike></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <strike><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, </code></strike></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <strike><code>alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></strike></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <strike><code>2-(4-morpholinyl)ethyl, whether or not further substituted </code></strike></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <strike><code>on the indazole ring to any extent: including, but not </code></strike></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <strike><code>limited to, APP-PICA and 5-fluoro-APP-PICA;</code></strike><code> </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>4-AcO-DMT;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>name 5-MeO-MIPT;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(78) 4-hydroxy Diethyltryptamine (4-HO-DET);</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(81) 4-hydroxy-N-methyl-N-isopropyltryptamine </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>(4-HO-MiPT); </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(82) </code><u><code>(Blank);</code></u><code> </code><strike><code>Fluorophenylpiperazine;</code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(83) Methoxetamine;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>ethcathinone). </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>substances having a depressant effect on the central nervous </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers, and salts of isomers </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>whenever the existence of such salts, isomers, and salts of </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>isomers is possible within the specific chemical designation:</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 69 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) mecloqualone;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) methaqualone; and</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) gamma hydroxybutyric acid.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>substances having a stimulant effect on the central nervous </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers, and salts of isomers:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Fenethylline;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) N-ethylamphetamine;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Aminorex (some other names:
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-amino-5-phenyl-2-oxazoline; aminoxaphen;
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-5-dihydro-5-phenyl-2-oxazolamine) and its
</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>salts, optical isomers, and salts of optical isomers;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Methcathinone (some other names:
</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-methylamino-1-phenylpropan-1-one;
</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Ephedrone; 2-(methylamino)-propiophenone;
</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>alpha-(methylamino)propiophenone; N-methylcathinone;
</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>methycathinone; Monomethylpropion; UR 1431) and its
</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>salts, optical isomers, and salts of optical isomers;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Cathinone (some trade or other names:
</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-aminopropiophenone; alpha-aminopropiophenone;
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-amino-1-phenyl-propanone; norephedrone);</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) N,N-dimethylamphetamine (also known as:
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>N,N-alpha-trimethyl-benzeneethanamine;
</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>N,N-alpha-trimethylphenethylamine);</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 70 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) 3,4-Methylenedioxypyrovalerone (MDPV); </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Halogenated amphetamines and
</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>methamphetamines - any compound derived from either
</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>amphetamine or methamphetamine through the substitution
</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>of a halogen on the phenyl ring, including, but not
</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>limited to, 2-fluoroamphetamine, 3-
</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>fluoroamphetamine and 4-fluoroamphetamine; </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Aminopropylbenzofuran (APB):
</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>including 4-(2-Aminopropyl) benzofuran, 5-
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>benzofuran, and 7-(2-Aminopropyl) benzofuran; </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Aminopropyldihydrobenzofuran (APDB):
</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Methylaminopropylbenzofuran
</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(MAPB): including 4-(2-methylaminopropyl)
</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>benzofuran, 5-(2-methylaminopropyl)benzofuran,
</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>6-(2-methylaminopropyl)benzofuran
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>and 7-(2-methylaminopropyl)benzofuran</code><u><code>;</code></u><code> </code><strike><code>.</code></strike><code> </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(13) Methylaminopropyldihydrobenzofuran</code></u><code> </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-</code></u><code> </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>N-methylpropan-2-amine.</code></u><code> </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 71 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) Temporary listing of substances subject to emergency </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>scheduling. Any material, compound, mixture, or preparation </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>that contains any quantity of the following substances:</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>(benzylfentanyl), its optical isomers, isomers, salts, and </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>salts of isomers;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) N-[1(2-thienyl) methyl-4-piperidyl]-N- </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>phenylpropanamide (thenylfentanyl), its optical isomers, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>salts, and salts of isomers.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) Synthetic cathinones. Unless specifically excepted, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>any chemical compound which is not approved by the United </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>States Food and Drug Administration or, if approved, is not </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>dispensed or possessed in accordance with State or federal </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>law, not including bupropion, structurally derived from </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>2-aminopropan-1-one by substitution at the 1-position with </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>either phenyl, naphthyl, or thiophene ring systems, whether or </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>not the compound is further modified in one or more of the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>following ways: </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) by substitution in the ring system to any extent </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>halide substituents, whether or not further substituted in </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>the ring system by one or more other univalent </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>substituents. Examples of this class include, but are not </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>limited to, 3,4-Methylenedioxycathinone (bk-MDA); </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) by substitution at the 3-position with an acyclic </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>alkyl substituent. Examples of this class include, but are </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 72 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>not limited to, 2-methylamino-1-phenylbutan-1-one </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>(buphedrone); or </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) by substitution at the 2-amino nitrogen atom with </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>inclusion of the 2-amino nitrogen atom in a cyclic </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>structure. Examples of this class include, but are not </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>limited to, Dimethylcathinone, Ethcathinone, and </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>a-Pyrrolidinopropiophenone (a-PPP); or </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Any other synthetic cathinone which is not approved by the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>United States Food and Drug Administration or, if approved, is </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>not dispensed or possessed in accordance with State or federal </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>law. </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) Synthetic cannabinoids or piperazines. Any synthetic </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>cannabinoid or piperazine which is not approved by the United </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>States Food and Drug Administration or, if approved, which is </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>not dispensed or possessed in accordance with State and </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>federal law.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(1) As used in this Section, "synthetic cannabinoid" </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <u><code>includes, but is not limited to, any compound, as </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <u><code>identified in a report from an accredited forensic </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <u><code>laboratory, that is structurally derived from any one or </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <u><code>more of the following compounds:</code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(A) Any compound structurally derived from </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>3-(1-naphthoyl)indole or </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>1H-indol-3-yl-(1-naphthyl)methane by substitution at </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>the nitrogen atom of the indole ring by alkyl, </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 73 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl whether or not further </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>substituted in the indole ring to any extent, whether </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted in the naphthyl ring to any extent. </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>Examples of this structural class include, but are not </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>limited to, JWH-018, AM-2201, JWH-175, JWH-184, and </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>JWH-185;</code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(B) 3-(1-naphthoyl)pyrrole by substitution at the </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the pyrrole ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>substituted in the pyrrole ring to any extent, whether </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted in the naphthyl ring to any extent. </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>Examples of this structural class include, but are not </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>limited to, JWH-030, JWH-145, JWH-146, JWH-307, and </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>JWH-368;</code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(C) 1-(1-naphthylmethyl)indene by substitution at </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>the 3-position of the indene ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl whether or not further </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 74 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>substituted in the indene ring to any extent, whether </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted in the naphthyl ring to any extent. </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>Examples of this structural class include, but are not </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>limited to, JWH-176;</code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(D) 3-phenylacetylindole by substitution at the </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indole ring with alkyl, </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>substituted in the indole ring to any extent, whether </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted in the phenyl ring to any extent. </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>Examples of this structural class include, but are not </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>limited to, JWH-167, JWH-250, JWH-251, and RCS-8;</code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(E) 2-(3-hydroxycyclohexyl)phenol by substitution </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>at the 5-position of the phenolic ring by alkyl, </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not substituted in </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>the cyclohexyl ring to any extent. Examples of this </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>structural class include, but are not limited to, CP </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>47, 497 and its C8 homologue (cannabicyclohexanol);</code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(F) 3-(benzoyl) indole with substitution at the </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indole ring by an alkyl, </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 75 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl group whether or not further </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>substituted in the indole ring to any extent and </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>whether or not substituted in the phenyl ring to any </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>extent. Examples of this structural class include, but </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>are not limited to, AM-630, AM-2233, AM-694, </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>Pravadoline (WIN 48,098), and RCS-4;</code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(G) 3-cyclopropoylindole with substitution at the </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, whether </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted on the cyclopropyl ring to any </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>extent, including, but not limited to, XLR11, UR144, </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>FUB-144;</code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(H) 3-adamantoylindole with substitution at the </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, whether </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted on the adamantyl ring to any </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 76 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>extent, including, but not limited to, AB-001;</code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(I) N-(adamantyl)-indole-3-carboxamide with </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>substitution at the nitrogen atom of the indole ring </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, whether </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted on the adamantyl ring to any </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>extent, including, but not limited to, APICA/2NE-1, </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>STS-135;</code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(J) N-(adamantyl)-indazole-3-carboxamide with </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>substitution at a nitrogen atom of the indazole ring </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>whether or not substituted on the adamantyl ring to </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>any extent, including, but not limited to, AKB48, </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>5F-AKB48;</code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(K) 1H-indole-3-carboxylic acid 8-quinolinyl ester </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>with substitution at the nitrogen atom of the indole </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 77 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, whether </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>or not substituted on the quinoline ring to any </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>extent, including, but not limited to, PB22, 5F-PB22, </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>FUB-PB-22;</code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(L) 3-(1-naphthoyl)indazole with substitution at </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>the nitrogen atom of the indazole ring by alkyl, </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>whether or not substituted on the naphthyl ring to any </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>extent, including, but not limited to, THJ-018, </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>THJ-2201;</code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(M) 2-(1-naphthoyl)benzimidazole with </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>substitution at the nitrogen atom of the benzimidazole </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the benzimidazole ring to any extent, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>whether or not substituted on the naphthyl ring to any </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>extent, including, but not limited to, FUBIMINA;</code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H- </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>indazole-3-carboxamide with substitution on the </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 78 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indazole ring by alkyl, </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, AB-PINACA, AB-FUBINACA, </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>AB-CHMINACA;</code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>1H-indazole-3-carboxamide with substitution on the </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indazole ring by alkyl, </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, ADB-PINACA, </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>ADB-FUBINACA;</code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>1H-indole-3-carboxamide with substitution on the </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 79 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, ADBICA, 5F-ADBICA;</code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H- </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>indole-3-carboxamide with substitution on the nitrogen </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>atom of the indole ring by alkyl, haloalkyl, alkenyl, </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, ABICA, 5F-ABICA;</code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(R) Methyl 2-(1H-indazole-3-carboxamido)- </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>3-methylbutanoate with substitution on the nitrogen </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>atom of the indazole ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, AMB, 5F-AMB;</code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(S) Methyl 2-(1H-indazole-3-carboxamido)- </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>3,3-dimethylbutanoate with substitution on the </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indazole ring by alkyl, </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 80 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, 5-fluoro-MDMB-PINACA, </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>MDMB-FUBINACA;</code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(T) Methyl 2-(1H-indole-3-carboxamido)-3- </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>methylbutanoate with substitution on the nitrogen atom </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>of the indole ring by alkyl, haloalkyl, alkenyl, </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, MMB018, MMB2201, and </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>AMB-CHMICA;</code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(U) Methyl 2-(1H-indole-3-carboxamido)-3,3- </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>dimethylbutanoate with substitution on the nitrogen </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <u><code>atom of the indole ring by alkyl, haloalkyl, alkenyl, </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole indole ring to any extent, </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, MDMB-CHMICA;</code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>indazole-3-carboxamide with substitution on the </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indazole ring by alkyl, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, alkenyl, cycloalkylmethyl, </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylethyl, aryl halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 81 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indazole ring to any extent, </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, APP-CHMINACA, </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>5-fluoro-APP-PINACA;</code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)- </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>1H-indole-3-carboxamide with substitution on the </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <u><code>nitrogen atom of the indole ring by alkyl, haloalkyl, </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >        <u><code>halide, alkyl aryl halide, </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the indole ring to any extent, </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>including, but not limited to, APP-PICA and </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>5-fluoro-APP-PICA;</code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(X) 1H-indazole-3-carboxylic acid 8-quinolinyl </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>ester with substitution at the nitrogen atom of the </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>indazole ring by alkyl, haloalkyl, alkenyl, </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>2-(4-morpholinyl)ethyl, whether or not further </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>substituted on the inazdole ring to any extent, </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>whether or not substituted on the quinoline ring to </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>any extent, including, but not limited to, SDB-005, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <u><code>5-F-SDB-005;</code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(2) As used in this Section, "synthetic piperazine" </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <u><code>includes, but is not limited to, any of the following </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <u><code>compounds and their positional isomers:</code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 82 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(A) N-Benzylpiperazine (BZP);</code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(B) Trifluoromethylphenylpiperazine (TFMPP);</code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(C) Fluorophenylpiperazine;</code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(D) Chlorophenylpiperazine.</code></u><code> </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(j) Unless specifically excepted or listed in another </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>schedule, any chemical compound which is not approved by the </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>United States Food and Drug Administration or, if approved, is </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>not dispensed or possessed in accordance with State or federal </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>law, and is derived from the following structural classes and </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>their salts:</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Benzodiazepine class: A fused 1,4-diazepine and </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>benzene ring structure with a phenyl connected to the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>1,4-diazepine ring, with any substitution(s) or </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>replacement(s) on the 1,4-diazepine or benzene ring, any </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>substitution(s) on the phenyl ring, or any combination </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>thereof. Examples of this class include but are not </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>limited to: Clonazolam, Flualprazolam; or</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Thienodiazepine class: A fused 1,4-diazepine and </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>thiophene ring structure with a phenyl connected to the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>1,4-diazepine ring, with any substitution(s) or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>replacement(s) on the 1,4-diazepine or thiophene ring, any </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>substitution(s) on the phenyl ring, or any combination </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>thereof. Examples of this class include but are not </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>limited to: Etizolam. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(k) Fentanyl-related substances.</code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(1) As used in this Section, "fentanyl-related </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 83 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <u><code>substance" means any compound, as identified in a report </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <u><code>from an accredited forensic laboratory, unless </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <u><code>specifically excepted or listed under another schedule, </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <u><code>that is not approved by the United States Food and Drug </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <u><code>Administration or, if approved, is not dispensed or </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <u><code>possessed in accordance with State or federal law and that </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <u><code>is structurally derived from fentanyl </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <u><code>(N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <u><code>propanamide) by one or more of the following </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <u><code>modifications:</code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(A) replacement of the phenyl portion of the </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <u><code>phenethyl group by any monocycle, whether or not </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>further substituted in or on the monocycle;</code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(B) substitution in or on the phenethyl group with </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >        <u><code>amino, or nitro groups;</code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(C) substitution in or on the piperidine ring with </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <u><code>alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>haloalkyl, amino, or nitro groups;</code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(D) replacement of the aniline ring with any </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <u><code>aromatic monocycle whether or not further substituted </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <u><code>in or on the aromatic monocycle; or</code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(E) replacement of the N-propionyl group by </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <u><code>another acyl group.</code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(2) "Fentanyl-related substance" includes, but is not </code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <u><code>limited to, the following substances:</code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 84 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(A) Acetyl-alpha-methylfentanyl;</code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta- </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <u><code>phenyl)ethyl-4-piperidyl) propionanilide; </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <u><code>1-(1-methyl-2-phenylethyl)-4-(N-propanilido) </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <u><code>piperidine;</code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2- </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <u><code>thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);</code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2- </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >        <u><code>phenethyl)-4-piperidinyl]-N-phenylpropanamide</code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(E) 3-Methylfentanyl (N-[3-methyl-1-(2- </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <u><code>phenylethyl)-4-piperidyl]-N-phenylpropanamide);</code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(F) 3-Methylthiofentanyl (N-[(3-methyl-1- </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >        <u><code>(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);</code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(G) Para-fluorofentanyl (N-(4-fluorophenyl)- </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >        <u><code>N-[1-(2-phenethyl)-4-piperidinyl]propanamide);</code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl- </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <u><code>4-piperidinyl]-propanamide);</code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(I) Beta-hydroxy-3-methylfentanyl (other name: </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <u><code>N-[1-(2-hydroxy-2-phenethyl)-3-methyl- </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <u><code>4-piperidinyl]-N-phenylpropanamide);</code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(J) Furanyl fentanyl (FU-F);</code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(K) Butyryl fentanyl;</code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(L) Valeryl fentanyl;</code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(M) Acetyl fentanyl;</code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(N) Beta-hydroxy-thiofentanyl;</code></u></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(O) Acrylfentanyl (acryloylfentanyl);</code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 85 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(P) Cyclopropyl fentanyl;</code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(Q) Crotonyl fentanyl;</code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(R) Methoxyacetyl fentanyl;</code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(S) Pentanoyl fentanyl;</code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(T) Cyclopentyl fentanyl;</code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(U) Isobutyryl fentanyl;</code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(V) Benzodioxolefentanyl;</code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><u><code>(W) Tetrahydrofuran fentanyl.</code></u><code> </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 103-245, eff. 1-1-24</code><code>.)</code><br> </td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(720 ILCS 570/206)</code><code>  </code><code>(from Ch. 56 1/2, par. 1206)</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 206. </code><code>(a) The controlled substances listed in this </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Section are included in Schedule II.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>another schedule, any of the following substances whether </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>produced directly or indirectly by extraction from substances </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>of vegetable origin, or independently by means of chemical </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>synthesis, or by combination of extraction and chemical </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>synthesis:</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Opium and opiates, and any salt, compound, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>derivative or preparation of opium or opiate, excluding </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>apomorphine, dextrorphan, levopropoxyphene, nalbuphine, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>nalmefene, naloxone, and naltrexone, and their respective </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>salts, but including the following:</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(i) Raw Opium;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(ii) Opium extracts;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 86 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iii) Opium fluid extracts;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(iv) Powdered opium;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(v) Granulated opium;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(vi) Tincture of opium;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(vii) Codeine;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(viii) Ethylmorphine;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(ix) Etorphine Hydrochloride;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(x) Hydrocodone;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xi) Hydromorphone;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xii) Metopon;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xiii) Morphine;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xiii.5) 6-Monoacetylmorphine; </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xiv) Oxycodone;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xv) Oxymorphone;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xv.5) Tapentadol; </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xvi) Thebaine;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xvii) Thebaine-derived butorphanol.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(xviii) Methorphan, except drug products </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >        <code>containing dextromethorphan that may be dispensed </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <code>pursuant to a prescription order of a practitioner and </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <code>are sold in compliance with the safety and labeling </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >        <code>standards as set forth by the United States Food and </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <code>Drug Administration, or drug products containing </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <code>dextromethorphan that are sold in solid, tablet, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >        <code>liquid, capsule, powder, thin film, or gel form and </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >        <code>which are formulated, packaged, and sold in dosages </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 87 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <code>and concentrations for use as an over-the-counter drug </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >        <code>product. For the purposes of this Section, </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >        <code>"over-the-counter drug product" means a drug that is </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >        <code>available to consumers without a prescription and sold </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >        <code>in compliance with the safety and labeling standards </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >        <code>as set forth by the United States Food and Drug </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >        <code>Administration. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Any salt, compound, isomer, derivative or </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>preparation thereof which is chemically equivalent or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>identical with any of the substances referred to in </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>subparagraph (1), but not including the isoquinoline </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>alkaloids of opium;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Opium poppy and poppy straw;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Coca leaves and any salt, compound, isomer, salt </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>of an isomer, derivative, or preparation of coca leaves </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>including cocaine or ecgonine, and any salt, compound, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>isomer, derivative, or preparation thereof which is </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>chemically equivalent or identical with any of these </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>substances, but not including decocainized coca leaves or </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>extractions of coca leaves which do not contain cocaine or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>ecgonine (for the purpose of this paragraph, the term </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>"isomer" includes optical</code><strike><code>, positional</code></strike><code> and geometric </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>isomers);</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Concentrate of poppy straw (the crude extract of </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>poppy straw in either liquid, solid or powder form which </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>contains the phenanthrine alkaloids of the opium poppy).</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 88 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>another schedule any of the following opiates, including their </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>isomers, esters, ethers, salts, and salts of isomers, whenever </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>the existence of these isomers, esters, ethers and salts is </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>possible within the specific chemical designation, dextrorphan </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>excepted:</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Alfentanil;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1.1) Carfentanil;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1.2) Thiafentanyl; </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Alphaprodine;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Anileridine;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Bezitramide;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Bulk Dextropropoxyphene (non-dosage forms);</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Dihydrocodeine;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Diphenoxylate;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Fentanyl;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Sufentanil;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9.5) Remifentanil;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Isomethadone;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) (Blank);</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Levorphanol (Levorphan);</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Metazocine;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Methadone;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Methadone-Intermediate,
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Moramide-Intermediate,
</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 89 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>acid;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(17) Pethidine (meperidine);</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(18) Pethidine-Intermediate-A,
</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-cyano-1-methyl-4-phenylpiperidine;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(19) Pethidine-Intermediate-B,
</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>ethyl-4-phenylpiperidine-4-carboxylate;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(20) Pethidine-Intermediate-C,
</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>1-methyl-4-phenylpiperidine-4-carboxylic acid;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(21) Phenazocine;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(22) Piminodine;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(23) Racemethorphan;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(24) (Blank);</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(25) Levo-alphacetylmethadol (some other names: </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>substances having a stimulant effect on the central nervous </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>system:</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Amphetamine, its salts, optical isomers, and salts </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>of its optical isomers;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Methamphetamine, its salts, isomers, and salts of </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>its isomers;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Phenmetrazine and its salts;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Methylphenidate;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 90 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Lisdexamfetamine. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>substances having a depressant effect on the central nervous </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers, and salts of isomers </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>whenever the existence of such salts, isomers, and salts of </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>isomers is possible within the specific chemical designation:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Amobarbital;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Secobarbital;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Pentobarbital;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Pentazocine;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Phencyclidine;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Gluthethimide;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) (Blank). </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>substances:</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Immediate precursor to amphetamine and </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>methamphetamine:</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(i) Phenylacetone</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>Some trade or other names: phenyl-2-propanone;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>P2P; benzyl methyl ketone; methyl benzyl ketone.</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Immediate precursors to phencyclidine:</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(i) 1-phenylcyclohexylamine;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 91 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(ii) 1-piperidinocyclohexanecarbonitrile (PCC).</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Nabilone.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 100-368, eff. 1-1-18</code><code>.)</code><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(720 ILCS 570/208)</code><code>  </code><code>(from Ch. 56 1/2, par. 1208)</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(Text of Section before amendment by P.A. 103-881</code><code>)</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 208. </code><code>(a) The controlled substances listed in this </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Section are included in Schedule III.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>substances having a stimulant effect on the central nervous </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers (whether optical </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>position, or geometric), and salts of such isomers whenever </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>the existence of such salts, isomers, and salts of isomers is </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>possible within the specific chemical designation;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Those compounds, mixtures, or preparations in </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>dosage unit form containing any stimulant substances </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>listed in Schedule II which compounds, mixtures, or </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>preparations were listed on August 25, 1971, as excepted </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>compounds under Title 21, Code of Federal Regulations, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>Section 308.32, and any other drug of the quantitative </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>composition shown in that list for those drugs or which is </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>the same except that it contains a lesser quantity of </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>controlled substances;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Benzphetamine;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 92 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Chlorphentermine;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Clortermine;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Phendimetrazine.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>substances having a potential for abuse associated with a </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>depressant effect on the central nervous system:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Any compound, mixture, or preparation containing </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>thereof and one or more other active medicinal ingredients </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>which are not listed in any schedule;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Any suppository dosage form containing </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt of </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>any of these drugs and approved by the Federal Food and </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration for marketing only as a suppository;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Any substance which contains any quantity of a </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>derivative of barbituric acid, or any salt thereof:</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.1) Aprobarbital;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.2) Butabarbital (secbutabarbital);</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.3) Butalbital;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.4) Butobarbital (butethal); </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Chlorhexadol;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Methyprylon;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Sulfondiethylmethane;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Sulfonethylmethane;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 93 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Sulfonmethane;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Lysergic acid;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Lysergic acid amide;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10.1) Tiletamine or zolazepam or both, or any salt of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>either of them.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for a tiletamine-zolazepam
</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>combination product: Telazol.
</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for Tiletamine:
</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for zolazepam:
</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of aspirin;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of acetaminophen;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 50 milligrams of pentazocine or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>any of its salts plus naloxone HCl USP 0.5 milligrams, per </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>dosage unit;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Ketamine;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Thiopental. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Nalorphine.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d.5) Buprenorphine. </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 94 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>preparation containing limited quantities of any of the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>following narcotic drugs, or their salts calculated as the </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>free anhydrous base or alkaloid, as set forth below:</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>unit, with an equal or greater quantity of an isoquinoline </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>alkaloid of opium;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active non-narcotic ingredients in </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) (blank);</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) (blank);</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) not more than 1.8 grams of dihydrocodeine per 100 </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) not more than 300 milligrams of ethylmorphine per </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>100 milliliters or not more than 15 milligrams per dosage </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) not more than 500 milligrams of opium per 100 </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams, or not more than 25 </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>milligrams per dosage unit, with one or more active, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 95 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>amounts;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) not more than 50 milligrams of morphine per 100 </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams with one or more active, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>amounts.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Anabolic steroids, except the following anabolic </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>steroids that are exempt:</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Androgyn L.A.;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Andro-Estro 90-4;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) depANDROGYN;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) DEPO-T.E.;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) depTESTROGEN;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Duomone;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) DURATESTRIN;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) DUO-SPAN II;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Estratest;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Estratest H.S.;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) PAN ESTRA TEST;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Premarin with Methyltestosterone;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) TEST-ESTRO Cypionates;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Testosterone Cyp 50 Estradiol Cyp 2;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Testosterone Cypionate-Estradiol Cypionate </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>injection; and</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Testosterone Enanthate-Estradiol Valerate </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>injection.</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 96 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) Hallucinogenic substances.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Dronabinol (synthetic) in sesame oil and </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>encapsulated in a soft gelatin capsule in a U.S. Food and </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration approved product. Some other names for </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>(-)-delta-9-(trans)-tetrahydrocannabinol.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) (Reserved).</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) The Department may except by rule any compound, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>mixture, or preparation containing any stimulant or depressant </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>substance listed in subsection (b) from the application of all </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>or any part of this Act if the compound, mixture, or </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>preparation contains one or more active medicinal ingredients </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>not having a stimulant or depressant effect on the central </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>nervous system, and if the admixtures are included therein in </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>combinations, quantity, proportion, or concentration that </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>vitiate the potential for abuse of the substances which have a </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>stimulant or depressant effect on the central nervous system.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 100-368, eff. 1-1-18</code><code>.)</code><br> </td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(Text of Section after amendment by P.A. 103-881</code><code>)</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 208. </code><code>(a) The controlled substances listed in this </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>Section are included in Schedule III.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 97 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>substances having a stimulant effect on the central nervous </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers (whether optical </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>position, or geometric), and salts of such isomers whenever </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>the existence of such salts, isomers, and salts of isomers is </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>possible within the specific chemical designation;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Those compounds, mixtures, or preparations in </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>dosage unit form containing any stimulant substances </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>listed in Schedule II which compounds, mixtures, or </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>preparations were listed on August 25, 1971, as excepted </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>compounds under Title 21, Code of Federal Regulations, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>Section 308.32, and any other drug of the quantitative </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>composition shown in that list for those drugs or which is </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>the same except that it contains a lesser quantity of </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>controlled substances;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Benzphetamine;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Chlorphentermine;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Clortermine;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Phendimetrazine.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>substances having a potential for misuse associated with a </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>depressant effect on the central nervous system:</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Any compound, mixture, or preparation containing </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>thereof and one or more other active medicinal ingredients </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 98 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>which are not listed in any schedule;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Any suppository dosage form containing </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt of </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>any of these drugs and approved by the Federal Food and </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration for marketing only as a suppository;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Any substance which contains any quantity of a </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>derivative of barbituric acid, or any salt thereof:</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.1) Aprobarbital;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.2) Butabarbital (secbutabarbital);</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.3) Butalbital;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.4) Butobarbital (butethal); </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Chlorhexadol;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Methyprylon;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Sulfondiethylmethane;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Sulfonethylmethane;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Sulfonmethane;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Lysergic acid;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Lysergic acid amide;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10.1) Tiletamine or zolazepam or both, or any salt of </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>either of them.</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for a tiletamine-zolazepam
</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>combination product: Telazol.
</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for Tiletamine:
</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for zolazepam:
</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 99 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of aspirin;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of acetaminophen;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 50 milligrams of pentazocine or </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>any of its salts plus naloxone HCl USP 0.5 milligrams, per </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>dosage unit;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Ketamine;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Thiopental</code><u><code>;</code></u><code> </code><strike><code>.</code></strike><code> </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(16) Xylazine.</code></u><code> </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Nalorphine.</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d.5) Buprenorphine. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>preparation containing limited quantities of any of the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>following narcotic drugs, or their salts calculated as the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>free anhydrous base or alkaloid, as set forth below:</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>unit, with an equal or greater quantity of an isoquinoline </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>alkaloid of opium;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) not more than 1.8 grams of codeine per 100 </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 100 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active non-narcotic ingredients in </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) (blank);</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) (blank);</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) not more than 1.8 grams of dihydrocodeine per 100 </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) not more than 300 milligrams of ethylmorphine per </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>100 milliliters or not more than 15 milligrams per dosage </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) not more than 500 milligrams of opium per 100 </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams, or not more than 25 </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>milligrams per dosage unit, with one or more active, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>amounts;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) not more than 50 milligrams of morphine per 100 </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams with one or more active, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>amounts.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Anabolic steroids, except the following anabolic </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>steroids that are exempt:</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Androgyn L.A.;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Andro-Estro 90-4;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 101 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) depANDROGYN;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) DEPO-T.E.;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) depTESTROGEN;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Duomone;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) DURATESTRIN;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) DUO-SPAN II;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Estratest;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Estratest H.S.;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) PAN ESTRA TEST;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Premarin with Methyltestosterone;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) TEST-ESTRO Cypionates;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Testosterone Cyp 50 Estradiol Cyp 2;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Testosterone Cypionate-Estradiol Cypionate </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>injection; and</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Testosterone Enanthate-Estradiol Valerate </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>injection.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) Hallucinogenic substances.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Dronabinol (synthetic) in sesame oil and </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>encapsulated in a soft gelatin capsule in a U.S. Food and </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration approved product. Some other names for </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>(-)-delta-9-(trans)-tetrahydrocannabinol.</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) (Reserved).</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) The Department may except by rule any compound, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>mixture, or preparation containing any stimulant or depressant </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">SB1773</td><td class="xsl" align="center">- 102 -</td><td class="xsl" align="right">LRB104 03029 RLC 13047 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>substance listed in subsection (b) from the application of all </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>or any part of this Act if the compound, mixture, or </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>preparation contains one or more active medicinal ingredients </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>not having a stimulant or depressant effect on the central </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>nervous system, and if the admixtures are included therein in </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>combinations, quantity, proportion, or concentration that </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>vitiate the potential for misuse of the substances which have </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>a stimulant or depressant effect on the central nervous </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>system.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 103-881, eff. 1-1-25.)</code><br> </td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 95. </code><code>No acceleration or delay. </code><code>Where this Act makes </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>changes in a statute that is represented in this Act by text </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>that is not yet or no longer in effect (for example, a Section </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>represented by multiple versions), the use of that text does </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>not accelerate or delay the taking effect of (i) the changes </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>made by this Act or (ii) provisions derived from any other </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Public Act.</code><br> </td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 99. </code><code>Effective date. </code><code>This Act takes effect January </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>1, 2026.</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
